CONFIDENTIAL  rTMS for Stimulant Use Disorders  
[STUDY_ID_REMOVED]  
Final Protocol Version  
November 10, 2023  
2 
   
  
 
NIDA CTN Protocol 0 108 
rTMS for Stimulant Use Disorders 
(STIMULUS)  
 
Lead Investigator s: 
Kathleen Brady, MD, PhD ; Madhukar H. Trivedi, MD  
National Project Director:  
Jenna L. McCauley, PhD  
 
Sponsor: National Institute on Drug Abuse (NIDA)  
 
November 10, 2023  
Version 7.0 

NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
1 Protocol Development Team  
Andrew Czysz, MD, PhD  University of [LOCATION_007] Southwestern Medical Center  
Karen Hartwell, MD  Medical University of South Carolina  
Jenna McCauley, PhD  Medical University of South Carolina  
Susan Sonne, PharmD  Medical University of South Carolina  
Kathleen Crum PhD  Medical University of South Carolina/Indiana University  
Russell Toll, PhD  University of [LOCATION_007] Southwestern Medical Center  
Thomas Carmody, PhD  University of [LOCATION_007] Southwestern Medical Center  
 
Emmes  
Jennifer McCormack, MS  Data and Statistics Center (DSC)   
Eve Jelstrom, CRNA, MBA  Clinical Coordinating Center (CCC ) 
 
Consultants  
Mark George, MD  Medical University of South Carolina Department of Psychiatry 
& Behavioral Sciences  
Colleen Hanlon, PhD  Wake Forest School of Medicine Department of Cancer Biology 
Department of Physiology & Pharmacology  
Kenzie Preston, PhD  National Institute on Drug Abuse Clinical Pharmacology and 
Therapeutics Research Branch 
David Epstein, PhD  National Institute on Drug Abuse Real- world Assessment, 
Prediction, & Treatment Unit  
Elliot Stein, PhD  National Institute on Drug Abuse Neuroimaging Research Branch  
 
NIDA CCTN  
Geetha Subramaniam, MD  CCTN Scientific Officer  
 
 
 
CONFIDENTIALITY STATEMENT  
This document is confidential communication. Acceptance of this document constitutes agreement by [CONTACT_62305][INVESTIGATOR_847762].
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178662] OF ABBREVIATIONS  ............................................................................................  8 
2.0 STUDY SYNOPSIS  ........................................................................................................10 
 Study Objectives  ......................................................................................................10  
 Study Design and Outcomes  ...................................................................................10  
 Sample Size and Study Population ..........................................................................10  
 Intervention and Duration .........................................................................................11  
 Assessments ...........................................................................................................11  
 Safety Reporting  ......................................................................................................12  
 Analyses  ..................................................................................................................12  
3.
0 STUDY SCHEMA ...........................................................................................................13 
 Key Research Site Roles  .........................................................................................14  
4.
0 INTRODUCTION  ............................................................................................................15 
 Background And Significance To The Field .............................................................15  
 Study Rationale  .......................................................................................................16  
 Risk/Benefit Assessment  .........................................................................................16  
 General Considerations  .....................................................................................16  
 Cocaine and Methamphetamine Use  ................................................................. 16 
 Cocaine Use Disorder  ........................................................................................17  
 Methamphetamine Use Disorder  ........................................................................18  
 Potential Risks of rTMS ......................................................................................18  
 Cautions  ............................................................................................................20  
5.
0 PRIMARY AIMS, OBJECTIVES, AND HYPOTHESES  ..................................................22 
 Primary Aim  .............................................................................................................22  
 Secondary Aims  ......................................................................................................22  
 Exploratory Aims  .....................................................................................................22  
6.
0 STUDY DESIGN  ............................................................................................................23 
 Overview of Study Design ........................................................................................23  
 Duration of Study and Visit Schedule  .......................................................................24  
7.
0 STUDY POPULATION  ...................................................................................................25 
 Participant Inclusion Criteria ....................................................................................25  
 Participant Exclusion Criteria ...................................................................................26  
 Participant Recruitment and Retention  ..................................................................... 27 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
3 
 Inclusion of Women and Minorities  ..........................................................................28  
 Retention Plan  .........................................................................................................29  
8.
0 SITE SELECTION  ..........................................................................................................30 
 Sites  ........................................................................................................................ 30 
 Rationale for Site Selection ......................................................................................30  
9.
0 OUTCOME MEASURES ................................................................................................31 
 Primary Outcome Measure – Feasibility  ..................................................................31  
 Secondary Outcome Measure – Efficacy ................................................................. 31 
 Exploratory Outcome Measure(s)  ............................................................................[ADDRESS_1178663] Release Forms  ................................. 32 
 Screening Assessment  ............................................................................................ 32 
 Randomization .........................................................................................................33  
 Treatment/Intervention  .............................................................................................33  
 rTMS and Sham  ................................................................................................. 33 
 Other Study Procedures:  ....................................................................................34  
 Safety Monitoring of Intervention  ........................................................................34  
 Cognitive -Behavioral Educational Intervention  ...................................................35  
 Clinical Deterioration “Rescue” Plan ................................................................... [ADDRESS_1178664] -Randomization Follow -Up 
Assessments ...........................................................................................................36  
 Collection of Biospecimens  ......................................................................................37  
 Premature Withdrawal of Participants  ......................................................................37  
 Discontinuing of Study Intervention ..........................................................................37  
 Study Pause Rules  ..................................................................................................37  
 Blinding  ....................................................................................................................38  
 Type of Blinding ................................................................................................. 38 
 Maintenance of Blind .........................................................................................38  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178665] Sheet  ...........................................................................................46  
 Phen- X Toolkit Core Tier 1  .................................................................................47  
 Additional Demographics  ...................................................................................47  
 Protocol Satisfaction Survey  ..............................................................................47  
 Quality of Life  .....................................................................................................47  
 Medical Assessments  ..............................................................................................47  
 Physical Examination  .........................................................................................47  
 Medical and Psychiatric History  .........................................................................47  
 Vital Signs  ..........................................................................................................48  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
5 
 Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse 
Device Effects (UADE)  ............................................................................................ 48 
 AEs, SAEs and UADEs  ......................................................................................48  
 Prior and Concomitant Medications  ................................................................... 48 
 Penetration of Blind Assessment  .......................................................................49  
 EEG Biomarker of Treatment Response  ............................................................49  
 Psychological Assessments  .....................................................................................49  
 Mini International Neuropsychiatric Interview Plus  .............................................49  
 Hospi[INVESTIGATOR_5620] (HADS)  ................................................49  
 The Pi[INVESTIGATOR_2272] (PSQI)  ........................................................49  
 Concise Health Risk Tracking – Participant Rated Module (CHRT- SR) Suicidal 
Behavior Evaluation  ...........................................................................................49  
 Concise Health Risk Tracking – Clinician Rated Module (CHRT -CR) .................50  
 Substance Use Assessments  ..................................................................................50  
 Timeline Follow -Back (TLFB)  .............................................................................[ADDRESS_1178666]  ........................................................................................52  
13.
0 TRAINING REQUIREMENTS  ........................................................................................53 
 Overall  .....................................................................................................................53  
 rTMS Training and Supervision................................................................................53  
14.
0 CONCOMITANT THERAPY/INTERVENTION  ...............................................................54 
 General  ....................................................................................................................54  
 Medications Prohibited/Allowed During Trial  ............................................................54  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
6 15.0  STATISTICAL DESIGN AND ANALYSES  .....................................................................55 
 General Design  ........................................................................................................55  
 Study Hypotheses  ..............................................................................................55  
 Primary and Secondary Outcomes (Endpoints)  .................................................55  
 Recruitment  .......................................................................................................56  
 Randomization and Factors for Stratification ......................................................56  
 Rationale For Sample Size and Statistical Power  ....................................................56  
 Precision Analysis  ..............................................................................................56  
 Power Analysis  ..................................................................................................58  
 Projected Number of Sites  .................................................................................61  
 Projected Number of Participants per Site  .........................................................61  
 Statistical Methods for Primary and Secondary Outcomes  .......................................61  
 Primary (Feasibility) Outcome  ............................................................................61  
 Secondary (Efficacy) Outcome  ...........................................................................[ADDRESS_1178667] (HIPAA)  ..............................69  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178668] (DSMB)  ........................................................73  
 Safety Monitor/Medical Monitor  ..........................................................................74  
 Adverse Events (AEs)  ........................................................................................74  
 Serious Adverse Events (SAEs)  .........................................................................74  
17.
0 DATA MANAGEMENT  ..................................................................................................75 
 Design and Development  .........................................................................................75  
 Site Responsibilities  ................................................................................................. 75 
 Data Center Responsibilities  ....................................................................................75  
 Data Collection  ........................................................................................................75  
 Data Acquisition and Entry  .......................................................................................76  
 Data Editing  .............................................................................................................76  
 Data Transfer/Lock  ..................................................................................................76  
 Data Training  ...........................................................................................................76  
 Data Quality Assurance  ...........................................................................................76  
18.
0 DATA SHARING, PUBLIC ACCESS AND PUBLICATIONS  .........................................77 
19.0  PROTOCOL SIGNATURE [CONTACT_1783]  ..................................................................................78 
20.0  REFERENCES  ...............................................................................................................79 
21.0  APPENDIX A: ADVERSE EVENT REPORTING AND PROCEDURES  .........................84 
 Adverse Event Reporting (Chart)  .............................................................................88  
22.
0 APPENDIX B: DATA AND SAFETY MONITORING PLAN (DSMP)  ..............................89 
 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178669] OF ABBREVIATIONS  
Abbreviation Definition  
AE Adverse Event  
BMI Body Mass Index  
CBT Cognitive Behavioral Therapy  
CCC  Clinical Coordinating Center  
CFR Code of Federal Regulations  
CHRT -CR Concise Health Risk Tracking – Clinician Rated  
CHRT -SR Concise Health Risk Tracking – Self Report Suicidal Behavior Evaluation  
CLIA  Clinical Laboratory Improvement Act  
CoC Certificate of Confidentiality  
CI Confidence Interval  
CRF Case Report Form  
CTN Clinical Trials Network  
CUD  Cocaine Use Disorder  
DCC  Data Coordinating Center  
DLPFC  Dorsolateral Prefrontal Cortex  
DSC  Data and Statistics Center  
DSM -[ADDRESS_1178670] for Nicotine Dependence  
FWA  Federalwide Assurance  
GCP  Good Clinical Practice  
HADS  Hospi[INVESTIGATOR_847763] & Accountability Act  
HIV Human Immunodeficiency Virus  
HSP Human Subjects Protection 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178671] Deviation  
SUD  Substance Use Disorder  
TAU Treatment As Usual  
TLFB  Timeline Follow -Back  
TMS  Transcranial Magnetic Stimulation 
UADE  Unantic ipated Adverse Device Effects  
UDS  Urine Drug Screen  
VAS Visual Analogue Craving Scale 
 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
10 2.0 STUDY SYNOPSIS 
 Study Objectives  
The primary objective of this study is to determine the feasibility of repetitive transcranial magnetic 
stimulation (rTMS) for individuals with moderate to severe cocaine or  methamphetamine  use 
disorder  (CUD/MUD). The secondary objective is to gather preliminary data on the efficacy of 
rTMS for individuals with moderate to severe CUD or MUD. The exploratory objectives include  
examining the impact of rTMS on self -reported substance use, craving, mood and anxiety, sleep 
monitored via actigraphy, retention in treatment, changes in health, lifestyle, and function, and 
resting connectome biomarkers  measured by [CONTACT_66594] . 
 Study Design and Outcomes  
The study will be a randomized, double- blind, sham -controlled trial comparing up to 30 sessions 
of rTMS targeting the left dorsolateral prefrontal cortex (DLPFC) versu s up to 30 sessions of sham 
rTMS delivered over an 8- week treatment period with follow- up visits occurring at end of treatment  
and at 12- and 16 -weeks following  randomization.  Relapse prevention- targeted Cognitive 
Behavioral Therapy ( CBT) modules also will be  available for use to all participants, via a mobile 
app. The primary outcome is focused on  feasibility: the percentage of participants who receive at 
least 20 rTMS sessions over the 8- week treatment period. The secondary outcome is focused on  
efficacy: the last UDS of each treatment week  (7 day period) will be used for the efficacy analysis 
and the percentage of negative UDS (out of 8 total) for methamphetamine or cocaine  will be the 
primary efficacy measure. Participants also will be asked to report daily on drug use, craving, 
ability to resist use,  and mood using a digital survey delivered on their mobile phones. Drug use 
will also be monitored with weekly Timeline Follow-B ack and UDS  collected at each treatment 
visit. Actigraphy will be used to monitor sleep during the treatment period. If available at the study 
site, e lectroencephalography (EEG) will be used to assess resting connectome biomarkers.  Self-
report survey measures will be used to assess additional exploratory outcomes.  
 Sample Size and Study Population  
Approximately 160 adults ( aged 18 -65) with moderate to severe cocaine use disorder (CUD ; 
n=80) or methamphetamine use disorder (MUD; n =80) interested in cutting down or stoppi[INVESTIGATOR_847764] . Participants who meet DSM -5 criteria for both CUD and MUD will be asked to 
choose which is the primary substance of choice to determine their diagnostic category . The study 
will be conducted across 4 sites  (with 2 sites  – Wake Forest , UT Health San Antonio  – 
discontinuing study participation early), and it is estimated that up to 80 participants will be 
enrolled at each site.  Sites may vary on total enrolled per site, but no more than 160 total 
participants will be enrolled across all sites. This sample size  provides adequate confidence 
interval length and provides greater than 80% power to detect medium -sized effect sizes, 
measured as odds ratios,  of greater than [ADDRESS_1178672] and significance level 
of 0.05  within each of CUD and MUD separately. Randomization will be stratified based  on current 
major depressive epi[INVESTIGATOR_1865] (MDE), study site and CUD or MUD. 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
11 
 Intervention and Duration 
Participants will be randomized to receive up to 30 sessions of rTMS or  up to  30 sessions of sham 
rTMS administered over an 8- week period (3- 5 treatments per week) . Prior to each rTMS/sham  
session , a cocaine or methamphetamine- related cue will be presented to the participant . 
Immediately after the cue presentation (while memory is reactivated) active or sham rTMS 
stimulation will be administered. Each rTMS/sham session will consist of 75 rTMS trains of 10 Hz 
for 4 seconds (40 pulses per train)  with inter -train interval (ITI) of 11 seconds (a total of 3000 
stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC). The rTMS coil (active or  
sham coil) will be placed over the left  DLPFC using the Beam F3 method . The interval between 
rTMS sessions will vary over the course of the study and for each participant depending on 
individual scheduling needs, with the primary objective being that each participant receives an adequate dose of treatment (at least 20 sessions) with flexibility in the timing of rTMS delivery to 
minimize study drop- out. Follow -up visits will be scheduled at the end of treatment  (within [ADDRESS_1178673] rTMS session), and at weeks 12 and 16. Completion of the study, including follow -
ups, will take  approximately  4 months (112 days) after randomization for individual participants.  
Recruitment is expected to take approximately 12- [ADDRESS_1178674] 20 treatment sessions  over the 8- week treatment period. Additional feasibility measures  will 
also include the following (as exploratory outcomes) : 
• Percent  of participants that complete  at least  75% of daily monitoring  
• Percent  of participants that complete all follow -up visits  
These outcomes will inform future decisions to conduct a larger randomized clinical trial designed 
to assess efficacy. Targets for the above feasibility measures are 75%.  
The secondary (efficacy)  outcome  measure will be  cocaine and methamphetamine use. This 
efficacy outcome  will be measured using the last  urine drug screens ( UDS ) collected for each 
treatment week  and the percent of negative UDS results  for cocaine or methamphetamine will be 
calculated.  
Exploratory measures include, but are not limited to: self-reported use (Timeline Follow -Back  
(TLFB) ), cocaine and/or methamphetamine craving ( Craving Assessment ), depression/anxiety 
symptoms (Hospi[INVESTIGATOR_5620]), sleep quality (Actigraphy; Pi[INVESTIGATOR_8326]) , the Health Related Quality of Life (HRQOL -4) assessment used by [CONTACT_268589], 
and resting connectome biomarkers measured by [CONTACT_66594].  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
12 
 Safety Reporting  
All adverse events (AE) will be solicited and collected from participants during treatment  visits  
and follow -up visits (or in -between visits if reported spontaneously). Reporting timeframes for 
AEs, serious AEs ( SAEs ), and unanticipated adverse device effects ( UADEs ) will follow FDA 
regulations for abbreviated IDE reporting ( 21 CFR 812) , as well as Institutional Review Board 
(IRB)  and sponsor  requirements . 
 Analyses  
The primary outcome (feasibility  — i.e., percent of participants who obtained at least 20 treatment 
sessions ) will be assessed along with a 95% confidence interval (CI)  using the Wilson method. 
The secondary  outcome ( efficacy — i.e., the percent of negative weekly UDS results over the 
treatment period) will be assessed using a generalized linear mixed  model incorporating 
treatment, site , week, stratum  (MDE) , and participant . Exploratory outcomes (e.g., daily self -
reports on drug use, craving, ability to resist use, depression/anxiety, sleep quality and mood) will 
be analyzed using Fisher exact tests, or other non -parametric two- sample tests, and generalized 
linear regression models, as appropriate.   
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
13 3.0 STUDY SCHEMA  
Figure 1 : Basic Study Schema 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Sham (Control) Arm 
Assessment  
(up to 30 sessions across 8 
weeks)  
rTMS (Intervention) Arm 
Assessment  
(up to 30 sessions across 8 
weeks)  
Baseline Assessment  
Randomization  
End of Treatment 
Assessment  
End of Treatment 
Assessment  
12-Week Post -
Randomization Assessment  
12-Week Post -
Randomization Assessment  
16-Week Post -
Randomization Assessment  
16-Week Post -
Randomization  Assessment  
Eligible Participants Identified  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
14 
 Key Research Site Roles  
Study sites will include the following key roles:  
• Site Principal Investigator (MD; DO; PhD)  
• Medical Clinician  (MD; DO ; NP; PA ) 
• rTMS Advanced Operator  
• rTMS Operator  (Optional)  
• Research Coordinator  
• Research Assistant  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
15 4.0 INTRODUCTION 
 Background And Significance To The Field 
The morbidity and mortality associated with methamphetamine use disorder (MUD) and cocaine 
use disorder (CUD) are high and are associated with serious psychiatric and physical 
consequences. Cocaine is one of the most commonly abused stimulants, with 2% of adults in the U.S. endorsing use within  the last year (Palamar et al., 2020 ), and use leads to negative 
consequences, including cognitive deficits, legal issues, and serious medical conditions, such as 
cardiovascular disease, kidney disease, and sexually transmitted diseases (Degenhardt and Hall, 2012; Cadet et al., 2015 ; Akinson et al ., 2009; Frazer et al., 2018). Methamphetamine is  a widely 
abused stimulant, and stimulants as a group are second to cannabis as the most widely abused 
illicit drug in the world (Degenhardt et al., 2016), and use in the U.S. has been increasing 
(SAMSHA, 2019) . MUD leads to similar negative consequences as CUD. Unfortunately, effective 
management for CUD and MUD remains elusive. Psychological interventions have demonstrated modest benefits, but relapse rates are high (Paulus et al., 2018) . There are currently no FDA -
approved pharmacotherapi[INVESTIGATOR_847765] (Morley et 
al., 2017) . 
TMS is a non -invasive brain stimulation technique which is approved for the treatment of major 
depressive disorder (MDD)  and most recently (August 2020) , the BrainsWay Deep TMS platform 
received FDA clearance as an aid for smoking cessation. rTMS refers to repetitive epi[INVESTIGATOR_847766], which is generally the protocol for therapeutic use.  There is ample basic science 
literature suggestive of specific circuit dysfunction that could be engaged by [CONTACT_847812] (Ekhtiari et al., 2019). While rTMS  targets superficial brain 
regions, typi[INVESTIGATOR_847767],  rTMS  can also impact deeper brain circuits critical for 
addiction, such as dopamine release in the caudate nucleus (Strafel la et al., 2001). A number of 
pi[INVESTIGATOR_847768] a variety of stimulation approaches, study designs, and outcomes (Rao et al., 2019). In one study, 10 individuals with CUD (5 per sham and active arms) underwent [ADDRESS_1178675] on cocaine use 
with active treatment (Bolloni et al., 2016). In a small pi[INVESTIGATOR_847769] (iTBS ; a form of TMS ) over the left DLPFC with 3 treatments per day over 10 
days (30 total  treatments ), 9 of the 14 participants who returned for 4- week follow -up showed 
reduction in total use and money spent on cocaine (Steele et al, 2019). Additionally, deep TMS (H-coil) at 20hz , over the bilateral medial and lateral prefrontal cortex , over 12 ses sions within 
one month , has shown evidence for reducing cocaine cravings (Rapenisi et al., 2016). In 
summary , a number of small studies have demonstrated promising findings with the use of rTMS 
to the DLPFC  in CUD, but there is methodologic al variability across studies , and not all studies 
measured cocaine use as an outcome (Grall -Bronnec et al., 2014; Hanlon et al., 2018). In 
addition, there are only two controlled studies exploring rTMS in MUD. Investigating DLPFC rTMS 
in MUD men (N=48) (L iu et al., 2019) and women (n=90) (Li ang et al., 2018) , both studies  reported 
significantly reduced craving and withdrawal symptoms in the rTMS group, but methamphetamine 
use was not measured. In looking across rTMS studies in substance use disorders, high 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
16 frequency (10- 20 hz) TMS over the left DLPFC has most consistently shown evidence for positive 
outcomes in CUD and MUD (Enokibara et al., 2016; Ekhtiari et al., 2019), although studies in 
MUD are limited . 
 Study Rationale  
CUD and MUD are on the rise in the U .S. today. These disorders have severe psychiatric and 
medical consequences and current treatments have only modest efficacy. Preliminary data 
suggests that rTMS might be efficacious in the treatment of CUD and MUD. This pi[INVESTIGATOR_847770], if positive, provide preliminary data about efficacy that could be used 
to design an adequately powered trial of rTMS in CUD and MUD.  The hypothesis is that the 
delivery of rTMS will be feasible as measured by [CONTACT_847813] 20  rTMS  treatment sessions. A secondary hypothesis is that 
rTMS, as compared to a sham rTMS treatment , will be efficacious as measured by [CONTACT_847814]. Study participants will be men and women, aged 
18-65, who meet criteria for moderate to severe MUD and/ or CUD. We have chosen to enter only 
those with moderate to severe disease to maximize the potential to see a change in cocaine or 
methamphetamine use. Because rTM S is an FDA -approved treatment for major depressi ve 
disorder  (MDD), we will stratify individuals based on current MDE.  
 Risk/Benefit Assessment  
 General Considerations  
The Magventure MagPro® stimulators R20, R30, R30 with MagOption, X100, and X100 with MagOption are all FDA 510(k) cleared for stimulation of peripheral nerves for diagnostic purposes (k160280, k061645, k091940) and for treatment of adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current epi[INVESTIGATOR_1865] (K172667).  
The recent K1726 67 approval was based upon substantial equivalence with a predicate device, 
previously deemed a non -significant risk device  by [CONTACT_1622].  Although the use of the Magventure 
MagPro® is not considered “ significant risk” by [CONTACT_847815], the precise risks in MUD 
and CUD are currently unknown. Given the potential morbidity and mortality associated with MUD and CUD and the lack of any FDA -approved treatments for these disorders, rTMS may be able 
to provide a viable treatment option. 
 Cocaine and Methamphetamine Use  
There is ample basic science literature in the addictions field suggestive of specific circuit 
dysfunction that could be engaged by [CONTACT_847816] (Ekhtiari et al., 2019). Several pi[INVESTIGATOR_847771] a variety of stimulation approaches, study designs, and outcomes (Rao et 
al., 2019; Liu  et al., 2018; Li ang et al., 2018). In looking across rTMS studies in substance use 
disorders, high frequency (10- 20 hz) TMS over the left DLPFC has most consistently shown 
evidence for positive outcomes in CUD and MUD (Enokibara et al., 2016; Ethairka et al., 2019), but these studies have limitations and further evidence is needed.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
17 In terms of safety, a 2014 review of rTMS studies for any substance use disorder found that the 
procedure was well tolerated. They note, “Eight studies did not specify rTMS tolerance, which 
was generally good, as shown in four studies in which no side effects were reported. Only one 
study reported a case of serious side effects “ seizure, probably due to discontinuing 
benzodiazepi[INVESTIGATOR_847772]” ( Grall -Bronnec & Sauvagnet, 2014). A recent review of the use of 
neuromodulation in addiction highlights that there is no evidence that standard TMS safety guidelines need to be adjusted for its use in substance use disorders (Ekhtiari et al, 2019). 
Nonetheless, they do recommend that studies should carefully report their methods, safety monitoring measures, and side eff ects assessments.  
Several small studies using rTMS  in both cocaine and methamphetamine use disorders have 
been performed with similar safety profiles as have been reported in Major Depressive Disorder. 
The stimulation parameters (site, coil type, frequency, intensity) of these studies are heterogenous. The parameters proposed in this study (10hz over the left DLPFC) have been used 
extensively in Major Depressive Disorder and they have only been previously reported in  
methamphetamine use disorder  (see Section 4.3. 4 below).  
As stated above,  the FDA recently cleared the BrainsWay Deep rTMS  platform for smoking 
cessation, making it the first substance use disorder to receive FDA clearance with any form of  
rTMS . In the pi[INVESTIGATOR_847773] 17.1% in the active arm and 7.9% 
in the sham arm (Zangen et al ., 2020). From a safety perspective, no seizures were reported, and 
adverse events were comparable to rTMS  studies in Major Depressive Disorder.  
In the current study, participants will be asked not to participate in any other formal treatment for 
CUD or MUD, except  self-help groups, while they are in this study. As such, there may be some 
risk of drug use that could be avoided if the individual were engaged in a formal SUD treatment 
program. However, all participants will receive access to and will be  encouraged to participate in 
a CBT for SUDs which will be provided to all study participants.  
 Cocaine Use Disorder  
In a study of [ADDRESS_1178676] stimulation ( iTBS ) 
sessions per day, with approximately a 60 -min interval between sessions, for 10 days over a 2-
week period (30 total iTBS sessions) was evaluated (Steele et al ., 2019). Authors note “iTBS was 
well-tolerated, despi[INVESTIGATOR_847774]. A single participant developed a 
transient neurological event of uncertain etiology on iTBS day 9 and cocaine- induced psychosis 
2 weeks after discontinuation.” A case report of this participant’s event was also published, and suggested that psychogenic seizure or tremor was the more likely etiology  (Steele et al ., 2018) . 
In a sham controlled study , participant s with CUD (N=6) received active treatment with twelve 
rTMS sessions, administered three times a week for 4 weeks at 100% of motor threshold, over 
bilateral PFC  (Bolloni et al, 2016) . The authors noted that other than one participant who 
experienced a mild headache, no other discomfort was observed during active treatment. Another study of rTMS of the frontal pole in cocaine users (n=25) reported  that the procedure was well  
tolerated and did not report any safety events (Hanlon et al ., 2017).  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
18 Rapi[INVESTIGATOR_847775] (2016) conducted an open label study of seven men with CUD . 
Participants  received alternate day 20  Hz deep transcranial magnetic stimulation ( dTMS ) in 20 
trains targeting the left DLPFC for 12 sessions spread over one month, with no complications or 
adverse events identified.  
 Methamphetamine Use Disorder  
In a sham -controlled study of 48 male participant s with MUD receiving 10 Hz rTMS for 10 minutes 
per session, targeting the left DLPFC for 10 treatments, no adverse events were reported and all 
participants in the active group (n=24) completed treatment  (Liang et al ., 2018).  Liu and 
colleagues  (2019) conducted a sham -controlled study of participant s with MUD in which 52 
subjects were assigned to the active 10  Hz group for 20 rTMS treatments. All completed the 
treatments, but no specific safety outcomes are r eported. They do note however, “the current 
study suggests that rTMS is a safe, tolerable, and effective for female substance abuse patients.”  
 Potential Risks  of rTMS  
Seizure: rTMS  can cause seizures, however the rate at which this happens is unknown. In a 
recent survey (Lerner et al., 2019) of rTMS laboratories and clinics between 2012 and 2016 (inclusive), respondents (N = 174) reported 24 seizures in an estimated 318,560 TMS sess ions 
(.08/1000 sessions). However, TMS delivered within published guidelines to subjects without recognized risk factors only caused 4 seizures (<.02/1000 sessions). Subject risk factors (e.g.,  
brain lesions and epi[INVESTIGATOR_002]) increased seizure risk. Seizures appeared more common when safety guidelines were exceeded. Stimulation with the parameters and settings we propose to use appears to cause fewer than [ADDRESS_1178677] the stimulus 
intensity based on the motor threshold, before beginning treatment.  
While the presence of a brain tumor or lesion might be a contraindication for  rT
 MS (although it is 
not always), this is typi[INVESTIGATOR_847776] -targeted cortical area. All participants will be asked if 
they have ever had a seizure or if any member of their family has ever had a seizure. They will 
be asked if they have any known tumors or lesions. They will be asked if they have ever had an 
abnorm al MRI or CT s can. They will be asked if they have ever suffered a head injury and/or have 
ever been unconscious for more than a few minutes. A positive response to any of these screening questions will warrant further evaluation by [CONTACT_847817]  (MC) who will 
determine if the participant is eligible for study participation.  
Potential for scalp discomfort, face pain, eye pain, toothache,  nau
 sea and headaches : Some 
people report some mild discomfort when the magnetic pulses are applied over the scalp,  which 
may be mitigated by [CONTACT_847818][INVESTIGATOR_15413]. Add itiona lly, some people (less than 10%) report 
face pain, eye pain, or toothache during administration of rTMS (O’Reardon et al ., 2007). Further, 
some  people (~ 25%) report headache following rTMS. However, the headaches are temporary, 
go away on their own within 60 minutes, and  are manageable with common over- the-counter pain 
remedies  (Loo et al., 2008) . 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
19 Potential worsening of mood with  rTMS : Several studies have so far demonstrated the feasibility 
of rTMS  as a treatment  for depression without any alarming indicators of exacerbation of 
symptoms. We evaluate mood at baseline and during the course of the study to evaluate for 
chang ing mood symptoms.  
Potential induction of m ania/hypomania with rTMS : There is limited evidence that rTMS can 
induce manic or hypomanic epi[INVESTIGATOR_1841]. In its use for Major Depressive Disorder, case reports of 
rTMS emergent manic epi[INVESTIGATOR_481079] (Rachid, 2017). This risk could be elevated 
in a substance abuse population, given that stimulant use is also associated with mania and 
hypomania. Mood symptoms will be evaluated throughout the course of study.  
Pot ential effects of  rTMS  on brain tissue : rTMS  is thought to be safe, with no brain damage, 
despi[INVESTIGATOR_411264]. We have reported a safety study looking at 
the MRI scans before and after [ADDRESS_1178678] also performed an MRI diffusion imaging study before and after  
rTMS /Functional Magnetic Resonance Imaging (fMRI ) study and found no deleterious effect of  
rTMS  on brain tissue at the site of stimulation.  
Potential hearing loss:  The discharge of the rTMS  coil generates a high- energy click that may 
cause cochlear damage. Humans exposed to rTMS  have shown temporary increases in auditory 
threshold (especially at high frequencies) lasting at least [ADDRESS_1178679] these changes and will be worn during rTMS  sessions  (Loo et al., 
2008) . 
Potential changes in cognitive function: There have been no reports of long- t
 erm changes (more 
than a minute) in cognitive function (memory, attention, etc .) in rTMS  studies (Galletly et al., 2016). 
Safety studies specifically looking for these changes did not find any effects of  rTMS  with the 
exception of one open study in which healthy volunteers were exposed to [ADDRESS_1178680].  The stimulation parameters exceeded the 
recommended safety range and there was no control for patient fatigue or other non -specific 
effects.  
Safety in case of pregnancy:  This protocol will exclude pregnant women. While the risks of using  
rTMS  with pregnant women are largely unknown and current evidence is limited to case studies , 
the theoretical risk of rTMS is thought to be low (due to the rapi[INVESTIGATOR_847777]) and case series evidence supports the safety of  rTMS  in 
pregnancy (Hizli et al., 2014; Eryilmaz et al., 2015). In fact, current thinking is that  rTMS  may 
ultimately be a safer tre atment for severe depression during pregnancy (and post -partum) than 
systemic medications, although more data are needed to confirm safety in pregnancy . 
Increased craving is a possible risk  due
  to cue exposure: Since study procedures includ e 
exposing participants to cocaine or methamphetamine cues, there is a chance that there may be a transient increase in craving scores. Craving will be rated at the end of  rTMS  and subjects will 
be held in a supervised setting until their craving reaches baseline level.  If participants continue 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178681] never had to hospi[INVESTIGATOR_18552] 
a participant for protracted craving . 
Metal implants and non -r emovable objects : Magnetic stimulation from the rTMS  coil may cause 
metal objects to heat, which could lead to injury. Thus, all participants will be screened for having 
implanted metal objects,  (with the exception of metallic dental fillings) , and will be asked to remove 
any metal jewelry or pi[INVESTIGATOR_847778] . 
Unknown Risks : rTMS i s an experimental procedure that has not been approved by [CONTACT_4760] 
a treatment for CUD or MUD and it may have unknown side effects  in this population. The 
researchers will let participants know if they learn anything that might make them change their mind about participating in the study.  
 Cautions  
In the current study, risks of rTMS will be minimized by [CONTACT_716]:  
1. Conduc ting a physical exam and medical history to rule out individuals in whom  rTMS  
may be unsafe  
2. Following published safety guidelines for rTMS administration 
3. Excluding individuals who may have vulnerabilities to possible side effects, including those with a history of seizure disorder , brain tumor or those with metallic implants 
above the waist  (with the exception of metallic dental fillings)  
4. Excluding pregnant women; conducting pregnancy tests periodically during the course of 
the trial  and requiring effective birth control during the treatment phase of the study  
5. Use of topi[INVESTIGATOR_63767] (if needed) to prevent skin discomfort 
6. Conducting motor threshold assessments by [CONTACT_847819] r TMS Operators  
7. Obtaining UDS prior to each rTMS session and if newly positive for drugs of abuse, re-
assessing the motor threshold prior to performing the rTMS  
8. Re-assessing the motor threshold following any block of 10 rTMS sessions without 
recalibration  
9. Assessing mood and suicidality at baseline and periodically during the course of the study  
10. Frequent evaluation of side effects/adverse events by a Medical Clinician  
11. rTMS sessions will be stopped at any point if the participant becomes uncomfortable  
12. Providing foam earplugs to minimize risk of transient hearing impairment 
Risks of EEG : Ther
 e are no associated risks of EEG. Skin irritation or discomfort may result 
from electrodes or cap.  
Psychological Stress:  So me questionnaires may result in feelings of  discomfort, upset, 
embarrassment , or disappoint ment . 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
21 Risks of T opi[INVESTIGATOR_523907] (EMLA, Lidocaine or Lidocaine/Prilocaine): A pplication site reactions 
(irritation, redness, swelling, stinging, burning), numbness in places where the cream is appl ied. 
There is also the risk of having an allergic reaction which could include hives, swelling to the face, 
throat, lips or tongue, itching, or difficulty breathin g. 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
22 5.0 PRIMARY AIMS, OBJECTIVES , AND HYPOTHESES  
 Primary Aim  
The primary objective of this pi[INVESTIGATOR_847779] 30 sessions of rTMS 
over the left DLPFC versus up to 30 sessions of sham rTMS for treatment of  individuals with CUD 
or MUD . The primary outcome is feasibility  — i.e., percent of participants who obtained at least 
20 treatment sessions. Additional feasibility outcomes will be assessed as exploratory outcomes . 
Primary H ypothesis : At least  75% of participants  who enter CTN -[ADDRESS_1178682] UDS per 
treatment week (7- day period) . This will be used to examine the effect size of rTMS versus sham 
to inform future clinical trials.  
Secondary Hypothesis :  Individuals who receive active rTMS will have a significantly higher % 
UDS negative results for methamphetamine  (if participants are designated in the primary MUD 
group)  or cocaine (if participants are designated in the primary CUD group)  over the course  of 
treatment , as compared to those in the sham group. 
 Exploratory Aims  
The exploratory objectives of this study are to examine other feasibility measures,  the impact of 
rTMS on self -reported substance use, craving, mood and anxiety, sleep monitored via actigraphy, 
resting connectome profile via EEG, retention in treatment, and changes in health, lifestyle, and 
function.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
23 6.0 STUDY DESIGN  
 Overview of Study Design  
The study will be a randomized, double- blind  pi[INVESTIGATOR_847780] 
(sham) in reducing stimulant use among individuals with CUD or MUD. Potential participants will 
be screened for eligibility and undergo an assessment process. Eligible and interested 
participants will be randomized to one of two groups; groups will receive up to 30 sessions of 
rTMS (or sham) over the course of an 8- week  treatment period. Assessments will be conducted 
at Screening , weekly during treatment, end of treatment,  and at 12- and 16- week s post-
randomization.  Participants will be compensated for participating in rTMS/sham sessions and 
assessments. UDS will be obtained at assessment sessions and prior to each treatment session 
from all participants.  
Given that psychosocial interventions remain the mainstay of treatment for CUD and MUD, we 
reason that clinical neuromodulation trials should be conducted in the context of concurrent psychosocial treatment. Inclusion of cognitive- behavioral treatment comprised of evidence- based 
components among all randomized conditions addresses the ethical obligation to provide treatment for participants. All participants will be asked to participate in [ADDRESS_1178683] use, mood, and 
sleep. These surveys will be delivered via ePRO  directly to the participants’ mobile device.  
Daily/nightly sleep and activity levels will be monitored in all participants using an ActiGraph 
device during the treatment period. If available at the study site electroencephalogram (EEG) 
measurements will be taken to facilitate identification of treatment response biomarkers.  
Given the preliminary nature of this study  (to better isolate the potential effects of rTMS from the 
effects of psychosocial substance abuse treatment), participants will not be engaged in formal 
substance abuse treatment. Participation in self -help groups  is allowed. Recruitment will therefore 
focus on individuals who are willing to try to decrease their cocaine and/or methamphetamine use, but are not engaged or plan to be engaged in formal  SUD treatment. If an individual is 
engaged in formal treatment a t the time of recruitment, but chooses to participate in the trial rather 
than continue treatment, no “wash- out” period will be required. Efforts will be made to advertise 
and recruit in local communities specifically for individuals interested in decreasing or stoppi[INVESTIGATOR_847781]/or methamphetamine use. It is anticipated that enrolled participants will only receive 
study -related interventions and  will not concurrently receive treatment as usual f rom the sites. 
However, if an enrolled individual decides to pursue formal treatment and remain in the study, data on time in treatment will be collected. Considering the rigorous time requirements of the 
rTMS protocol and the fact that we will be providing CBT modules for participant use, we do not 
anticipate that this will be an issue.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
24 
 Duration of Study a nd Visit Schedule  
Participants are expected to be engaged in the study for approximately  4 months ( with 8 weeks 
of rTMS/ sham plus 2 months of follow -ups). This study is expected to last approximately 2 years, 
including site initiation and close- out activities. 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178684]: 
Table 1: Participant Inclusion Criteria  
Criterion  Rationale  
1. Be aged 18- 65, inclusive.  Defines study population.  
2. Have a diagnosis of moderate or severe Cocaine 
or Methamphetamine Use Disorder (CUD/MUD) 
over the past 12 months (as determined by [CONTACT_2681] -5 
diagnostic criteria).  Recruiting participants with moderate or 
severe CUD or MUD will allow  detection  of 
rTMS versus sham effects, that may not be 
apparent with mild CUD or MUD.  
3. Have used cocaine or methamphetamine on at 
least [ADDRESS_1178685] 30 days (based on TLFB).  Participants must have a current CUD or 
MUD. 
4. Be interested in decreasing cocaine and/or 
methamphetamine use Defines study population.  
5. If female, willing to use appropriate birth control 
method during the treatment phase of the study  
(see list below) . Safety  
6. Be able to understand the study procedures and 
provide written informed consent to participate in 
the study.  To comply with ethical standards, and to 
ensure adherence to study procedures, participants must be able to understand the 
study procedures, risks, and benefits.  
7. If prescribed benzodiazepi[INVESTIGATOR_847782], must be on a stable dose for at 
least [ADDRESS_1178686] the motor 
threshold  
 
Appropriate birth control methods  include:  
a. Oral contraceptives , contraceptive patch , hormonal vaginal contraceptive ring;  
b. Barrier (diaphragm or condom) ; 
c. Contraceptive implant ; 
d. Medroxyprogesterone acetate injection; 
e. Intra-uterine device  
f. Complete abstinence from sexual intercourse ; 
g. Surgical sterilization  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
26 
 Participant Exclusion Criteria  
All individuals meeting any of the exclusion criteria will be excluded from study participation.  
Exclusion criteria will include the following:  
Table 2: Participant Exclusion Criteria  
Criterion  Rationale  
1. A DSM -[ADDRESS_1178687] . The present study has been specifically 
designed to target, and assess effects of rTMS  
versus sham  on, CUD or MUD. Defines study 
population.  
2. History of a serious medical disorder that, in 
the opi[INVESTIGATOR_847783] , would 
make it unsafe to participate in the study or 
may prevent collection of study data. Treatment for a serious medical disorder 
should take precedence over this experimental treatment  for SUD . A serious medical disorder 
could interfere substantially with engagement in the treatment, negatively influencing feasibility and efficacy outcomes . 
3. Is currently engaged in formal SUD 
treatment . This pi[INVESTIGATOR_847784] (versus sham) in the context of 
a self -guided CBT program.  
4. Documented history of unprovoked seizure 
(lifetime) or any seizure in the past 6 months.  Seizure is a risk associated with rTMS.  
5. Documented history of brain lesion(s) and/or 
tumor(s). The presence of a brain tumor or lesion might 
be a contraindication for r TMS ( i.e., where 
seizure threshold is significantly lowered due 
to the lesion or if the lesion is on the r TMS -
targeted cortical area).  
6. Metal implants or non- removable metal 
objects above the waist1. Participant safety . 
7. Currently pregnant . While there is no available evidence to date 
suggesting that r TMS is harmful during 
pregnancy, the risks of using rTMS with 
pregnant women are unknown.  
8. Lifetime history of prior clinical treatment 
with TMS   Prior TMS exposure will unblind active and 
sham groups.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
27 Criterion  Rationale  
9. Current or lifetime bipol ar disorder . Mania and hypomanic epi[INVESTIGATOR_847785] r TMS.  
Individuals with comorbid posttraumatic stress 
disorder , anxiety disorders, and/or depressive 
disorders will be allowed to participate. 
Individuals will be screened for current MDE , 
as randomization will be stratified by [CONTACT_847820] (among other 
factors).  
10. Current psychotic disorder  or psychotic 
depression. In order to keep the population for this pi[INVESTIGATOR_847786], individuals with 
psychotic disorders will be excluded. 
11. Serious risk of  homicide or suicide.  Participant safety .  
12. Are a prisoner or in police custody at the 
time of eligibility screening.  Prisoner or police custody status would 
preclude engagement in the study, which 
involves multiple in -person treatment  and 
follow- up visits.  
13. Previously randomized as a participant in 
the study.  Participants may only enroll in the study once  
14. Planned admission to a residential 
treatment facility or other formal SUD treatment program.  This pi[INVESTIGATOR_847787] (versus sham) in the context of a self -guided CBT program. Formal treatment 
for SUD would interfere with assessment of study outcomes.  
15. Unwilling or unable to follow study 
procedures.  Study procedures must be followed, both for 
participants’ safety and to allow assessment of 
study outcomes.  
1with the exception of metallic dental fillings  
  
 Participant Recruitment a nd Retention  
Participants will be recruited from multiple sources at each of the 4 study sites. Individuals will be 
pre-screened by [CONTACT_3647], and those who are likely to meet DSM -5 criteria for C UD and/or 
MUD will be invited for study assessments. Individuals who meet all inclusion criteria and who do 
not meet any exclusion criteria will be randomized to a study condition and participate in the study 
intervention and associated assessments.  rTMS/sham will occur in the context of self- guided CBT 
modules. However, participants will not receive other treatment for SUD at the site while they are 
participating in the study. Thus, participants must be willing to have the study intervention serve 
as their sole SUD treatment during study participation, other than self -help groups.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178688] ( sIRB). Screening and 
enrollment logs will be maintained at each study site; for each potential participant, information 
will be documented regarding source of initial information about the study  — including referral 
source, if applicable; reasons for ineligibility at the screening assessment levels; and reasons for 
non-participation of eligible participants . 
 Inclusion of Women and Minorities  
A variety of study sites will be selected to promote the attraction of a diverse study population.  
Study sites should aim at recruiting participants comparable to national demographic 
characteristics of past month cocaine and methamphetamine users. See T able 3 below. The 
demographic characteristics may vary slightly from site to site based on underlying regional demographic differences. If difficulty is encountered in recruiting an adequate number of women and/or minorities, the difficulties involved in recruitment will be discussed in national conference 
calls and/or face -to-face meetings, encouraging such strategies as linkages with medical sites 
and or treatment programs that serve a large number of women and/or minorities, advertising in newspapers or radio stations with a high female/minority readership/listening audience, etc.  
Table 3: Demographic Characteristic Percentages in Past Month Cocaine and 
Methamphetamine Users Aged 18 or older: Results from NSDUH 2018 
Characteristic  Cocaine  Methamphetamine  
GENDER    
Male  68 64 
Female  32 36 
HISPANIC ORIGIN AND RACE    
Not Hispanic or Latino  84 82 
White  58 73 
Black or African American  17 2.5 
AIANa 0.4 2.3 
NHOPIb 0.3 * 
Asian  0.4 0.8 
Two or More Races  4 4 
Hispanic or Latino  16 18 
a American Indian and Alaskan Native  
b Native Hawaiian and Other Pacific Islander  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
29 * = low precision  
 
Ref: SAMSHA, Center for Behavioral Health Statistics and Quality, National Survey on Drug 
Use and Health, [ADDRESS_1178689] 
methods (e.g., phone call, text, email) with appointment reminders approximately 1 week, and 
again 1 day prior to  the incentivized follow- up assessments.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178690], we will recruit over approximately a 22-month period with a 2-
month follow -up period (occurring on a rolling basis) . Each site is  expected to recruit 
approximately 3-[ADDRESS_1178691] ration of  rTMS as part of a research study 
recruitment and the management of  the needs of individuals with SUDs. Specifically, participating 
sites should:  
1. Be able to rely on the MUSC IRB as the single IRB (sIRB) of record  
2. Have an r TMS  operator  (or other individual certified in rTMS  administration procedures)  
and Medical Clinician  experienced in administering active and sham rTMS  
3. Have access to the MagVenture MagPro ® X100 system properly equipped for double 
blinding for use during this study  
4. Be able to recruit enough individuals with CUD and/or MUD to meet study recruitment 
goals  
5. Have previous experience enrolling individuals with CUD  and MUD in clinical trials  
6. Be willing to randomize participants to active rTMS versus sham conditions  
7. Have ability to conduct rTMS and sham sessions on weekends  
8. Be able to provide after hours clinical backup for study -related emergencies  
9. Be willing /able to provide payment to participants for attendance and assessment 
completion  
 Rationale for Site Selection  
We will choose sites with experience administering rTMS to facilitate timely study start -up and 
reduc tion of  initial costs and time associated with site training. In order to evaluate the feasibility 
of treating stimulant use disorders with rTMS, we must start with teams that have successfully administered this therapy in the past. Further more , meeting the targeted sample size requires the 
ability to recruit  individuals with CUD or MUD who are seeking treatment. Therefore, we will 
choose sites with experience in conducting research with and treating this population.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
31 9.0 OUTCOME MEASURES  
 Primary Outcome Measure – Feasibility  
The primary objective of this pi[INVESTIGATOR_847788]  [ADDRESS_1178692] will constitute the primary feasibility 
outcome.  
 Secondary Outcome Measure – Efficacy  
The secondary objective of the study is to examine the effect size of up to 30 sessions of rTMS 
over the left DLPFC versus 30 sessions of sham  rTMS  on cocaine or methamphetamine use in 
individuals with CUD or  MUD (respectively) . The efficacy outcome will be  determined using the 
last UDS in each treatment week. The  percent of negative UDS from these 8 samples will be 
presented as a continuous measure. A negative drug screen for participants in the CUD group 
would be a UDS absent of cocaine; a negative drug screen for participants in the MUD group would be a UDS absent of methamphetamine. 
 Exploratory Outcome Measure( s) 
Exploratory objectives of this study include examining the impact of rTMS on self -reported 
substance use, craving, mood and anxiety, sleep monitored via actigraphy, resting connectome 
profile via EEG,  retention in treatment, and changes in health, lifestyle, and function. Additional 
feasibility outcomes will be explored, including the following:  
• Percent of participants that complete at least 75% of daily monitoring  
• Percent of participants that complete all follow -up visits  
 Study Timeline  
After receiving CCTN approval of the final protocol, approximately 6-9 months of trial preparation 
activities will elapse prior to commencing enrollment/randomization. Trial preparation will include obtaining IRB approval, developi[INVESTIGATOR_268468], developi[INVESTIGATOR_847789]  (MOP) , conducting all research staff training, and sites’ securing CLIA Certificates of 
Waiver (as needed),  collecting required regulatory documents  and endorsing sites. If feasible, the 
study may be implemented in a single wave; however, sites may launch on a rolling basis of 1- [ADDRESS_1178693] completion of the recruitment phase. Two months will  
be allowed for data lock after the end of the follow -up period. Therefore, data lock is projected to 
occur at approximately 2 7-30 months after CCTN approval of the final protocol.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
32 10.0 STUDY PROCEDURES  
 Pre-Screening  
Participants will be recruited at each study site. Potential participants responding to recruitment 
materials or otherwise referred to the study will be pre -screened on the phone or in person to 
ascertain preliminary eligibility status. A series of questions wil l determine preliminary eligibility, 
and formal screening appointments will be scheduled for those who meet these eligibility criteria . 
A waiver of signed/documented consent  and a waiver of HIPAA authorization will be obtained 
from the sIRB for pre -screening.  
 Informed Consent Procedures  
Prior to the initiation of any study procedures, written informed consent and HIPAA authorizations will be obtained from participants  by [CONTACT_847821]. Potential participants will 
be given a copy of the IRB -approved consent form and asked to read it either on site or at home 
in accordance with the consent process approved by [CONTACT_17359]. Those who remain interested after receiving an explanation of the study will be given a short quiz  prior to signing the consent form  
to test their underst anding of the project, the purpose and procedures involved, and the voluntary 
nature of their participation. Those who cannot successfully answer quiz items will have the study 
re-explained by [CONTACT_9872] a focus on aspects they did not understand.  Anyone who 
cannot demonstrate appropriate understanding of the study by [CONTACT_847822]/false quiz correctly will be ineligible to participate and will be assisted in finding other treatment resources. Those who demonstrate understanding of the study and voluntarily agree to participate will be asked to sign the informed consent form and proceed with the screening 
assessments. As part of the informed consent procedures, participants will be asked to provide 
or decline consent to be contact[CONTACT_7678].  After passing the quiz and signing the 
consent form, participants will be given a copy of t he signed form to keep for their records.  
 HIPAA Authorization  and Medical Record Release Forms  
Each site will utilize a HIPAA Authorization, either combined into the consent or as a separate 
document , allowing study access to protected health information obtained by [CONTACT_163400], 
and in the participant’s medical record, as required by [CONTACT_268603] . Sites will be responsible 
for communicating with their local IRBs or Privacy Boards and obt ainin g appropriate  approvals or 
waivers as dictated by [CONTACT_30107]’ reliance agreement with the sIRB to be in regulatory compliance. 
 Screening Assessment  
After consenting to participate in the study, participants will start the screening assessment phase. Ideally, the screening assessment procedures will be completed in two visits, but they can be 
completed in more visits if necessary.  The screening assessment procedures must  be completed 
within two weeks prior to randomization.  
To determine study eligibility , the site’s Medical Clinician will review all source documentation 
related to inclusion and exclusion criteria. Women of childbearing potential must have a negative 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178694] the day of randomization (before randomization can proceed).  Please see Section 
12, Table 6 for details of screening and randomization assessments. 
 Randomization 
Following determination of full study eligibility  via screening, and completion of baseline 
assessments , participants will be randomly assigned to one of the two conditions (rTMS or sham) 
for 8 weeks. Random assignment will be on a 1:1 ratio to one of the two conditions. Randomization 
will be stratified by [CONTACT_3885] , presence/absence of current major depressive epi[INVESTIGATOR_1865], and primary 
CUD or MUD designation . The randomization procedure will be conducted centrally through the 
CTN DSC, and randomization assignments will not be conveyed to local research staff or 
participants . The randomization schedule will be programmed into the rTMS  machine so that 
neither the participant nor the rTMS  Operator  or research staff knows what condition was 
assigned. The DSC statistician will generate the randomization schedule using balanced blocks 
of varying sizes within strata to ensure lack of predictability along with relative equality of 
assignments across treatment groups. The DSC statistician will review randomization data on a 
regular basis to ensure that the scheme is being implemented according to plan. A randomization 
slot, once used, will not be re -allocated, due to the intent -to-treat nature of the study.  
 Treatment/Intervention  
Prior to receiving the first active/sham rTMS  intervention, the participant will meet with the 
Advanced TMS Operator  to determine the participant’s motor threshold (MT). See S ection 11 .2 
for description.  Once  the participant motor threshold has been determined, participants will 
receive either active rTMS or sham rTMS  treatment  as determined at Randomization  
 rTMS and S ham 
Either repetitive transcranial magnetic stimulation (rTMS) or sham (control) will be delivered to 
study participants during treatment sessions after exposure to approximately 5 minutes of 
imaginal (script -based) and visual methamphetamine (for MUD participants) or cocaine- related 
cues  (for CUD participants). The delivery of active versus sham intervention will be controlled by 
a dual active/sham coil. Administration of active versus sham  rTMS  will be determined by [CONTACT_847823]; randomization status will have been entered into files used by [CONTACT_847824]. With this procedure, rTMS Operators  and other research 
staff will be kept blind to participants’ condition assignment s. The coil will be placed to stimulate 
the left DLPFC. Section 11 provides specific  rTMS  parameters and considerations.  
Prior to each rTMS/sham session, cues designed to activate craving will be presented. At the first 
session, participants  will complete a triggers worksheet. At each subsequent  session, participants  
will be presented with their completed worksheet and aske d to imagine that they  are re-
experiencing a time when they were tempted to use and to imagine the pleasure they would 
experience following use. This will continue for approximately one minute, then a set of slides with 
photographs of cue situations and objects will be presented for approximately two minutes . The 
post-cue craving assessment will be completed and the rTMS/sham session will begin afterwards . 
Craving and ability to resist use will also be assessed upon completion of the rTMS/sham 
treatment session . 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
34 Research staff will maintain study visit logs throughout the study  period to monitor intervention 
adherence. Research staff will manage assessment and intervention appointment scheduling. 
Treatment sessions will be offered daily during the work week, with flexibility to allow occasional 
evening and weekend appointments, as well as multiple treatment sessions in one day  (maximum 
2 per day, 5 per study week ). 
 Other Study Procedures:  
Actigraphy : After randomization, participants will be issued an ActiGraph to assess daily sleep 
quality during weeks 1- 8. The ActiGraph GT9X Link wristband device is an FDA cleared device. 
Information obtained from the device includes, but is not limited to, sleep latency, sleep duration, 
and intervals of waking during the sleep period. Participants will be provided with the device and necessary accessories for wear and battery charging. Research staff will download data from the 
device once a week. The participant will return the device at the end of treatment  visit. 
Electroencephalography (EEG) : If available at the study site, EEG will be obtained after 
randomization and again at week 4, to explore the potential for EEG to be used as a biomarker 
of treatment response. The week 4 EEG will only be obtained for those participants for whom the 
EEG was conducted at randomization. Participants will wear a cap that will fit snugly on their head 
for this procedure. It is a quick and well -tolerated procedure to measure the summed electric 
potential of the brain measured at the scalp. Resting- state EEG will be recorded (5 minutes resting 
eyes open, 5 minutes resting eyes closed).  The post -hoc analyses of the EEG provide a whole-
brain connectomic profile (Toll, et al. , 2020) before and after the course of treatment, revealing 
changes in functional brain connectivity.  For this study, EEG will be performed at randomization 
and again at week 4  at study sites equipped to perform EEG. These analyses are considered 
exploratory. The fronto- parietal control network is known to function aty pi[INVESTIGATOR_847790] (Stewart et al, 2016). 
Additionally, longitudinal EEG recorded in adults at onset of abstinence from cocaine produced 
activation topographies consistent with the salience network which is integral to cue -related 
processing (Parvaz et al. , 2016). Having established that specific functional networks are known 
to be atypi[INVESTIGATOR_847791]- state EEG can resolve these 
networks’ connectivity, an excellent opportunity presents to explore the diagnostic potential of 
EEG in CUD/MUD and its ability to predict therapeutic response to rTMS . 
 Safety Monitoring of Intervention  
Intervention tolerability and effects will be systematically assessed before and after each 
treatment . This includes assessing for factors that impact seizure threshold (e.g. , increased 
stimulant use). Retesting of MT may occur as outlined in the  rTMS  intervention section below. 
Participants will be encouraged to contact [CONTACT_847825]; however, information on adverse 
events and medication changes also will be  collected during assessment and intervention 
appointments. The Study Medical Clinician  will meet with  the participant before, during , or after 
any study intervention if the rTMS  Operator  or participant is concerned for the potential of a 
serious adverse event , including seizure. If suspected seizure occurs during study intervention, 
the Study Medical Clinician  will arrange for the participant to be transferred to local emergency 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
35 room for further management. In the event of a seizure during the s tudy, the participant will be 
discontinued from further study inte rvention.  
 Cognitive -Behavioral Educational Intervention  
Participants in both conditions (rTMS and sham) will also participate in a CBT for SUD educational 
intervention that will be delivered via a mobile application platform developed and managed by 
[CONTACT_847826]. Twenty (20) self -guided modules will deliver evidence- based CBT and 
motivational strateg ies and educational therapeutic content to participants. Participants will be 
asked to complete 2 -3 modules per week during the treatment phase (rTMS or sham). Modules 
are brief (less than 30 minutes to complete), contain both didactic and interactive content (i.e., activitie s to reinforce didactic content), are available anytime, and may be completed in single or 
multiple “sessions.” Modules may be completed in any order. Participation will be tracked but will 
not be incentivized. Session topi[INVESTIGATOR_539563] a brief summary of content are provided in Table 4 below.  
Table 4: Cognitive Behavioral  Educational  Session Topi[INVESTIGATOR_847792]: Disease of Addiction  Signs of addiction: loss of control and Overview of disease of 
addiction  
Triggers (learning about triggers): Part 1  Identifying personal triggers and reaction (positive and negative) to them  
Triggers (practice scenarios): Part 2  Practice 3 scenarios identifying triggers, and subsequent reaction/behavior  
Healthy Copi[INVESTIGATOR_206517]: Part 1  Planning for encountering triggers and introduction to healthy copi[INVESTIGATOR_847793]: Part 2 Avoiding triggers and managing/copi[INVESTIGATOR_847794]: Part 1  Planning for triggers, implementing healthy copi[INVESTIGATOR_112272], attaining sober support  
Relapse Prevention Plan: Part 2  Implementing a healthy copi[INVESTIGATOR_847795]: Part 3  Identifying sober support and putting relapse prevention plan into practice  
Relapse Prevention Tips: Part 1  Avoiding relapse: Skills training for HALT, urge surfing, and setting healthy boundaries  
Relapse Prevention Tips: Part 2  Reviewing HALT, urge surfing, and boundary setting  
Building Discrepancy – Decision Making 
Skills  Focus on evaluating & responding vs. reacting; Differentiating 
between healthy vs. unhealthy copi[INVESTIGATOR_847796]: Part 1  Introducing tripartite model and evaluating thoughts for cognitive 
distortions  
Cognitive Behavioral Model: Part 2  Reviewing CBT model and introducing reframing  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178695]  
Self-Care Assessment  Building a healthy lifestyle via activities that promote physical, 
mental & emotional heath  
Dealing with Stressors  Defining stress and identifying warning signs of chronic stress 
(e.g., fatigue)  
Mindfulness  Introducing core mindfulness components of awareness and 
acceptance; Mindfulness practice exercise  
Grounding Techniques  Teaching techniques including: (1) Refocusing on present moment during uncomfortable feelings, distressing memories, triggers, and (2) 5-4-3-2- 1 exercise and practice  
Using Your Strengths  Identifying personal strengths and their role in achieving personal goals  
 Clinical Deterioration “Rescue” Plan  
A clinical deterioration “rescue” plan will be in place for participants who experience psychiatric 
or SUD deterioration during the study. Symptoms will be monitored closely throughout the trial to 
assess for deterioration (e.g., using the suicidality items on the Concise Health Risk Tracking questionnaire).  Those who endorse suicidal thou ghts or intent on the CHRT- SR will be further 
assessed on the CHRT- Clinician Rated assessment . Appropriate intervention will be arranged for 
any participant demonstrating gross clinical deterioration or suicide risk. The rescue measures 
will include referral for appropriate clinical intervention, including removal from the study and 
referral to SUD treatment should the participant demonstrate increasing substance use. 
 Follow- up 
The study intervention will last 8 weeks ( approximately 30 rTMS sessions ). The research team 
will conduct follow- up assessments at the end of treatment and at weeks [ADDRESS_1178696] timing of the follow -up assessments in order to 
accommodate participants’ schedules and to allow for either in- person or electronic 
communication (e.g., phone or other HIPAA compliant mechanism ). In the event that follow- up 
visits are conducted remotely, the UDS will not be performed. 
 Referral for Participants Needing Continued Treatment  
At the end of study participation (the last follow -up visit) , if a participant requires or requests 
continuing treatment for CUD and/or MUD  (as well as other SUDs), an appropriate treatment 
referral will be made.  
 End of Treatment Assessment a nd [ADDRESS_1178697] randomization and will be conducted by [CONTACT_3647]. Printed reminders for the 
follow- up assessments will be given to the study participant during the end of treatment  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
37 assessment appointment. In addition, research staff  will send a reminder in the mail/text/email/or 
social media (based on study participant preference) about 7 days prior to the scheduled follow -
up with an additional reminder notification via mail/text/email/or social media (based on study 
participant preference) the day before the scheduled follow -up. The end of treatment visit may 
occur on the day of the last treatment in week 8, or up to 1 week later. Week 12 and 16 f ollow- up 
visits may occur  no more than 1 week prior  to the visit or 2 weeks after the scheduled visit.  See 
Section 12 for assessments to be completed. 
 Collection of Biospecimens  
Urine samples will be collected from all participants for urine drug screen  (UDS) , the main efficacy 
outcome measure of the study. This will occur at screening, randomization,  during each treatment 
session prior to beginning the intervention, during the end of treatment  visit and follow -up 
assessments ( UDS will be omitted if  follow- up visits are per formed remotely) . A newly positive 
UDS will result in recalibration of the motor threshold before rTMS delivery. For females  of child -
bearing potential , a urine pregnancy test will be administered. Results of the urine pregnancy test 
will be obtained prior to performing the UDS, at screening, randomization,  at weeks [ADDRESS_1178698] -randomization will result in the cessation of rTMS/sham treatment. The research staff 
will follow the participant until an outcome of the pregnancy is known and reported.  
 Premature Withdrawal o f Participants  
All participants will be followed for the duration of their participation in the study unless they 
withdraw consent, die, or the investigator or sponsor decides to discontinue their enrollment for any reason. Reasons for the investigator or sponsor terminating a participant from the study may 
include, but are not limited to, the participant becoming a threat to self or others,  the participant  
acquiring an exclusionary condition,  lack of funding, or Data and Safety Monitoring Board ( DSMB ) 
early termination of the study for safety reasons.  
Should participants be lost to  follow- up, efforts to pursue participant locator information such as 
multiple contact [CONTACT_329006] (e.g., phone, address, email, social media) and collateral contact [CONTACT_268605]. At any time, participants may decide that they no longer wish to 
continue to participate in the study.  
 Discontinuing of Study Intervention 
Efforts will be made to continue follow -up of participants who discontinue the study intervention, 
but remain in the study for follow -up. 
 Study Pause  Rules 
The safety and preliminary efficacy of using rTMS to assist those with SUD has been evaluated 
in several studies ( see Rao et al., 2019). Nevertheless, the study DSMB will have access to all 
adverse events and other reportable events. Should the DSMB (or sponsor) determine that the study should be temporarily suspended or terminated,  the Lead Investigator s will work with the 
sIRB  of record and each of the participating sites to promptly inform them of the reasons for study 
termination or temporary suspension and to identify the circumstances in which the study may 
resume.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
38 The following study stoppi[INVESTIGATOR_847797] a review by [CONTACT_4318]:  
• Two or more participants experience severe (Grade 3) neurological reactions  
• One serious, unexpected and related adver se reaction 
 Blinding 
 Type of B linding  
This is a double- blind, sham -controlled study.  
 Maintenance of Blind 
With the exception of specified individuals at the DSC and the safety staff at the CCC, all other 
study personnel and participants will remain blind to intervention status until completion of the trial at all study sites. A Data and Safety Monitoring Board (DSMB) will review study data. DSMB 
reports will be blinded, though the blind may be broken in the closed session upon request.  
 Breaking the B lind 
In rare cases, it may be necessary to break the blind for a particular participant before completion of the trial (e.g., pregnancy or other medical necessity). The request to break the blind for an 
individual participant will be made by [CONTACT_847827]/or site Principal  Investigator.  
Unblinding the participant should only occur in cases of medical emergency when knowledge of 
the treatment group investigational method may be necessary for clinical management and decision- making. The decision to break the blind for a participant will be made jointly by [CONTACT_847828]/Medical Monitor and at least one of the Lead or site Principal  Investigators.  
 Participant Remuneration  
Because of the expected difficulty of maintaining high follow -up rates in the study population, 
adequate compensation for time and inconvenience is critical. Compensation will be in accordance with the IRB of record’s policies and procedures, subject to IRB approval, and will 
occur on the following study ac tivities : 
• Consent and baseline data collection  
• Treatment session attendance 
• Daily assessment  
• End of treatment  assessment  
• Week 12 follow- up assessment  
• Week 16 follow- up assessment  
• Completion of EEG  (if available at the study site)  
• Returning smart -phone device
 or to reimburse for data plan usage for those who 
used their own device  
NIDA CTN-0108   Version 7.0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
39 Compensation will occur following each visit with procedures specified in the SOP. Sites may 
reimburse participants directly for mileage expenses based on procedures specified in site 
operating procedures (SOPs ).  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
40 11.0 rTMS INTERVENTION 
 Overview  
Study participants will be randomized to receive up to 30 sessions of either active rTMS or sham 
across 8 weeks. Flexible treatment appointments will be offered, with every effort made to schedule participants for 3- 5 sessions/week. Stimulation will follow FDA -approved protocol for 
Major Depressive Disorder: 10  Hz stimulation at 120% of the motor threshold intensity and a total 
of [ADDRESS_1178699] sites to using a specific device 
model, as long as the device is capable of delivering this stimulation protocol with sham treatment 
above.  
 Structure And Content Of Treatment Sessions  
Resting MT will be determined prior to initial treatment using the Parameter Estimation by 
[CONTACT_538785] (PEST) algorithm. A revised MT will be determined in the following clinical 
scenarios:  
1. If UDS becomes positive for methamphetamine or cocaine after previously being 
negative.  
2. If participant reports increased methamphetamine or cocaine use since last treatment.  
3. If participant has had 10 treatments without repeat motor threshold determination.  
4. Study Medical Clinician  determines, based on their clinical judgement, seizure threshold 
has decreased for any other reason. 
Whenever MT is retested, treatment intensity for the following  rTMS  sessions will be based on 
the revised MT. 
Topi[INVESTIGATOR_15413]  (e.g., EMLA, Lidocaine or Lidocaine/Prilocaine) may be applied prior to 
rTMS/sham to help reduce scalp discomfort.  
Prior to each treatment stimulation onset, a set of cocaine or methamphetamine- related cues will 
be presented to the participant. Immediately after the offset of the cue presentation (while memory 
is reactivated) active or sham rTMS stimulation will be administered. 
Each treatment session will consist of 75 rTMS trains of 10 Hz for 4 seconds with inter -train 
interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left DLPFC (19 minutes). 
These parameters are consistent with those recommended in a r ecent consensus statement for 
rTMS treatment for Major Depressive Disorder (McClintock et al ., 2018).  
The rTMS  coil will be placed over the DLFPC using the Beam F3 method. Participants in the 
control group will receive sham treatment in a similar manner. Administration of active versus sham rTMS will be determined by [CONTACT_847829]; randomization status will have been entered into files used by [CONTACT_847830].  Treatment 
assignment will not be revealed to the participants or study personnel (double- blind). To improve 
treatment tolerability, a ramp- up will be u sed where the stimulation intensity is gradually increased 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
41 during the treatment session.  Participants will be expected to ramp to full intensity by [CONTACT_847831]/placebo session; however, participants will not be excluded if they are unable to tolerate 
the full treatment dose. Rather , ramp up will be attempted every 5 sessions and dose will be 
documented.  
 Sham rTMS  
Adequate sham stimulation protocols are a critical factor in clinical trials to ensure that effects can 
be ascribed specifically  to rTMS . Since  rTMS  generates sensory perceptions, such as clicking 
sounds, and muscle contractions (Conde et al., 2019), sham strategies aim to mimic the sight, 
sound, and feel of real stimulation, while attempting to avoid any direct neuronal effects on the 
central nervous  system. The delivery of active versus sham intervention will be controlled by a 
dual active/sham coil. Administration of active versus sham rTMS will be determined by [CONTACT_847829]; randomization status will have been entered into files used by [CONTACT_847824]. With this procedure, rTMS Operators  and other research 
staff will be kept blind to participants’ condition assignments. In the sham condition, participants and staff will hear identical sound as active treatment, but the magnetic field will be delivered in the opposite direction (away from the brain). Additionally  all participants will be equipped with 
small electrodes on the scalp adjacent to the magnetic coil. In the sham condition, the device will 
discharge a very mild electrical stimulation through those electr odes to mimic the tactile sensation 
of the magnetic field. This stimulation can cause muscle twitching and tactile sensation, but unlike 
magnetic stimulation does not penetrate the brain.  For participants with prior  rTMS  exposure, the 
lack of tactile sensation from the magnetic field in the sham condition could lead to unblinding and hence prior exposure is exclusionary for study participation. Sham  rTMS  approaches require 
further development but are sufficient in clinical settings in which patients are general ly naïve to  
rTMS  as will be the case in this study  (Duecker & Sack, 2015; Y. Levkovitz et al., 2015; C.E. 
Sheffer et al., 2013).  
 Scheduling  
Every effort will be made to be flexible in scheduling rTMS  visits, including Saturday and after -
hours sessions (site resources permitting) and scheduling 2 rTMS  sessions on 1 day (site 
resources permitting). Participants will receive study intervention over [ADDRESS_1178700]-randomization.  
The interval between rTMS  sessions will vary over the course of the study and for each participant 
depending on individual scheduling needs, with the primary objective being that each participant receives an adequate dose of treatment (at least 20 sessions) with flexibility in the  timing of  rTMS  
delivery to minimize study drop- out. The target minimum number of treatments is [ADDRESS_1178701] 1 hour apart, from 
NIDA CTN-0108   Version 7.0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178702] treatment session ended. Therefore, some participants may be able to receive 5 
treatments a week in 3 calendar days . 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178703] feasibility and participant burden. Screening w ill evaluate full 
eligibility, including diagnosis of CUD and/or MUD and other psychiatric diagnoses. The study 
clinician must review and approve all safety and eligibility assessments to confirm participant 
eligibility prior to randomization. Excluding collection of study participant characteristics and locator information, the participant baseline data will include past alcohol and drug use including 
cocaine and methamphetamine using the Timeline Follow -Back (TLFB) method, use of other 
substances, quality of life, and other data chosen to evaluate the efficacy of rTMS in stimulant 
users (e.g., sleep). Table 5 provides a listing of administrative/data collection forms, and Table 6 
includes the schedule for study specific assessments and procedures.  
Table 5: Administ rative Forms/Data Collection
 
 SC RND  Double -Blind Treatment Phase  Post FU FU 
Study Week  0 0 1 2 3 4 5 6 7 8 EOT 12 16 
Pre-Screen Summary  X             
Randomization Enrollment Form  X             
Daily  rTMS  Treatment Log    X X X X X X X X    
Visit Documentation    X X X X X X X X X X X 
Protocol Deviation Form  - - - - - - - - - - - - - 
End of Treatment Form            X   
Study Completion              X 
Mental Health Assessment Follow -up - - - - - - - - - - - - - 
Serious Adverse Event Summary  - - - - - - - - - - - - - 
Inventory Medication and Supplies  - - - - - - - - - - - - - 
Actigraph Device Discontinuation    - - - - - - - - X   
EEG Completion  (if available)   X    X        
- Completed as necessary  
 Administrative Forms  
 Pre-Screen Summary  
This form provides the lead team with basic information for each potential participant pre -
screened from each site. 
 Randomization Enrollment  
The Randomization Enrollment  form collects information regarding eligibility during the screening 
phase. Eligibility will be re -assessed prior to randomization. Only participants who continue to 
meet study eligibility criteria will be allowed to continue with the screening process and randomization.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178704] visits.  If a visit is missed for any reason, this form will 
capture the reason a study visit was missed. Completing this form and indicating that the visit was 
not attended, will remove the requirement for all assessments scheduled for that visit. Active tracking and follow -up should be performed for all missed visits. The form also captures specific 
data collection settings if applicable (such as in clinic, offsite, or remote).  
 Protocol Deviation  Form  
This form should be entered into the electronic data capture system whenever a protocol deviation 
occurs. This form will document a description of the deviation, how it occurred, the corrective 
action taken to resolve the specific deviation, as well as a description of the plan implemented to prevent future occurrences of similar deviations. This form will also capture protocol deviations 
that were a result of COVID -19 specific restrictions.  
 End of Treatment Form  
This form tracks the participant’s status with regard to the study intervention. It will be completed at the end  of treatment visit or at the end of the treatment visit window . 
 Study Completion Form  
This form tracks the participant’s status i n the study. It is completed at the week  [ADDRESS_1178705] be completed if the participant endorses suicidal thoughts in the Concise Health Risk Tracking – Self Report (CHRT -SR) Suicidal Behavior Evaluation. The completion of 
the Mental Health Assessment form documents that a clinician has been notified. The site is 
required to  have the participant  evaluated by a qualified clinician in accordance with  the site’s 
specific SOP.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178706] information on when the participant stopped using/wearing the actigraph device, as well as the reason for discontinuation of use. 
 EEG Completion  
For sites equipped to conduct EEG assessments, t his form documents whether the EEG was 
completed, and if not, why the EEG was not performed. The form is completed after randomization and again at week 4.  
Table 6 : Schedule of Assessments and Procedures 
 SC RND  Double -Blind Treatment Phase  Post FU FU 
Study Week  0 0 1 2 3 4* 5 6 7 8* EOT^ [ADDRESS_1178707] Form   X - - - - - - - - - -  
PhenX Toolkit Core Tier 1♯ 
Demographics  X             
Treatment Status Form  X             
Quality of Life  X          X X X 
Self-Report of HIV testing  X             
Tobacco  Use History  X             
Alcohol and Other Substance Use  X             
Medical Assessments  
Physical Exam  X             
Medical and Psychiatric History  X             
Vital Signs  X  
 X   X    X X   
Adverse Events  - - - - - - - - - - - - - 
Prior/Concomitant Medications¥ X - - - - - - - - - - - - 
Penetration of Blind Assessment       X     X  X 
Electroencephalogram (EEG)  (if available)   X    X        
Psychological Assessments  
MINI 7.0.2  X             
Hospi[INVESTIGATOR_5620] 
(HADS)  X X X X X X    X X X X 
Pi[INVESTIGATOR_2272]  X     X    X  X X 
CHRT -SR Suicidal Behavior Evaluation¥ X  X X X X X X X X X X X 
CHRT -CR Suicidal Behavior Evaluation  -  - - - - - - - - - - - 
Substance Use Self -Report  
TLFB¥ X  X X X X X X X X X X X 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178708] FU FU 
Study Week  0 0 1 2 3 4* 5 6 7 8* EOT^ [ADDRESS_1178709] for Nicotine Dependence  X     X     X X X 
Cue Craving Assessment€   X X X X X X X X    
Other Assessments  
Protocol Satisfaction Form            X   
Daily Mobile Survey∞   X X X X X X X X X X X X 
Actigraphy   X X X X X X X X X    
Lab Testing  
Urine Drug Screen  X  X X X X X X X X X X X 
Urine Pregnancy Test‡ X X    X    X    
SC=Screening/Assessment,  RND=Randomization,  EOT=End of Treatment, FU=Follow -Up,tobacco smokers only, 
‡females only, ♯required by [CONTACT_133312]/CCTN. Timepoints 1- 8 represent weeks of treatment; ¥assessment will occur weekly 
during the 8-week treatment/sham phase, €assessment will occur after cue presentation and end of  rTMS session at 
each visit during the treatment/sham phase; ∞assessment will occur daily during the treatment/sham phase, and 
throughout the follow -up period. ( -) indicates administration as appropriate. ^EOT will also be completed for participants 
who withdraw early from the study.*If either weekly  visits [ADDRESS_1178710] in finding participants during study 
participation. This form collects the participant’s current address, email address, and phone 
numbers. In order to facilitate locating participants if direct contact [CONTACT_200843], 
addresses and phone numbers of family/friends who may know how to reach the participant are collected. Social security number, driver’s license number and other information will be collected to aid both in searches of public records (for locating participants in the above scenario) and 
issuing appropriate tax documents based on participant compensation. This information will be 
collected on paper at screening and will be updated at each visit or whenever the participant 
reports a change in locator information. No information from this form is used in data analyses.  
 EMA Contact [CONTACT_108798]  
A system -based form will be used to collect participant’s email address  and mobile number . This 
information will be used to distribute daily mobile surveys assessing cocaine or methamphetamine 
related outcomes to participants, and will be updated by [CONTACT_847832], mobile numbers and/or email addresses throughout the course of the study.  In addition, 
participants will be able to unsubscribe or re- enroll to the mobile surveys during the course of the 
study, and site staff will also have the ability to unsubscribe or re- enroll participants to receive 
mobile surveys within the system.  

NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
47 
 Phen- X Toolkit Core Tier 1  
The Substance Abuse and Addiction Collection of the Phen- X Toolkit 
(http://www.phenxtoolkit.org/ ) includes measures that are being adopted across NIDA -f unded 
research. The Core Tier 1 collection includes measures for demographics (age, ethnicity, gender, 
race, educational attainment, employment status, marital status), BMI, and self-report of HIV test ; 
substance use measures include age of onset, past [ADDRESS_1178711] information regarding gender identity and sexual 
orientation.  
 Protocol  Satisfaction Survey  
Participants will complete a Protocol  Satisfaction Survey  at the end of treatment visit. If the 
participant does not attend that visit, it should be completed at the next attended visit (either the 
week [ADDRESS_1178712]-randomization follow -up visit. This form will assess the acceptability of study 
procedures, time, compensation, treatment intervention and other aspects of their experience, including a free- response (qualitative) item regarding how the treatment/intervention made them 
feel. 
 Quality of Life  
Partic ipants will complete a standardized quality of life assessment used by [CONTACT_847833] (BRFSS), the Health Related Quality of Life 
(HRQOL -4) measure. This form assesses health -related quality of life in the past 30 days, and 
includes an overall self -reported rating of general health (from ‘Poor’ to ‘Excellent’). This form is 
collected at screening, EOT, week 12, and week 16. 
 Medical Assessments 
 Physical Exam ination  
A brief physical exam will be performed by [CONTACT_847834]. For staff/participant 
convenience, this may be done at Randomization as long as it is completed prior to randomization.  
 Medical and Psychiatric History  
The study clinician obtains a medical and psychiatric history from the participant covering past 
and present health conditions to help determine eligibility and to provide baseline information. This is collected during screening. For staff/participant convenience, this may be done at 
Randomization as long as it is completed prior to randomization.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
48 
 Vital Signs  
Valid measures of height (at screening only) weight, blood pressure, and pulse will be collected 
at screening, initial treatment visit in week 1, initial treatment visit in week 4 , initial treatment visit 
in week 8 and end of treatment . 
 Adverse Events (A Es), Serious Adverse Events (S AEs), and 
Unanticipated Adverse Device Effects (U ADE ) 
 AEs, SAEs and UADEs  
At each visit the study staff assesses for AEs and SAEs by [CONTACT_413574], “How have you been feeling since your last visit?”  AEs and SAEs may also be spontaneously reported 
to study staff at any visit following consent.  The Medical Clinician will review all AEs at least 
weekly. Any AE suggesting medical or psychiatric deterioration will be brought to the attention of 
a Medical  Clinician immediately for further evaluation and management.  Similarly, any SAE will 
be brought to the attention of the Medical Clinician immediately for further evaluation and reporting 
as required. Visits will emphasize overdose risk and risk -management; any reported overdose is 
recorded as an AE or SAE. AE and SAE reporting are according to the reporting definitions and procedures outlined in the protocol and in accordance with applicable regulatory requirements.  
Device safety data will include the incidence of SAEs (e.g., worsening depression, suicidal 
ideation, suicide attempt, suicide, switching to hypomania/mania, seizure, death, and device malfunction resulting in patient or operator injury). In accordance with FDA recommendations, this 
protocol includes a suicide severity rating scale (CHRT) to assess both suicide intent and 
behavior. Incidence of common adverse events such as headache, application site pain will be 
collected, as well as discontinuation rate due to adverse events. Severity and duration of each 
AE will be determined. Data on each AE will include information about the intervention that was 
performed and whether the event was resolved. In addition, study staff will assess participants for 
signs of  UADE, and will bring potential UADEs to the Medical Clinician for evaluation. Any UADE 
identified will be reported in accordance with applicable regulatory requirements (i.e. , reported to 
the IRB for an abbreviated IDE as regulated under 21 CFR 812).  
Any events that meet the definition of an AE and/or SAE are reported on the AE/SAE form set. Any spontaneous reporting of withdrawal symptoms by [CONTACT_9893]: withdrawal symptoms reported at visits without scheduled specific structured questionnaires; and withdrawal symptoms not listed in the specific structured 
questionnaires reported at any visit.  
 Prior and Concomitant Medications  
For safety purposes, all medications taken by [CONTACT_9894] 30 days prior to screening, 
during screening, and during the active study will be documented on a Prior/Concomitant Medications assessment. All medications taken by [CONTACT_847835] -approved by [CONTACT_847817].  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
49 
 Penetration of Blind Assessment  
Participants and primary study personnel will be asked whether they think the participant is 
receiving rTMS or sham. This will be collected at the initial visit of treatment week 4 , end of 
treatment , and final Follow -Up visit (week 16). 
 EEG Biomarker of Treatment Response  
Electroencephalography (EEG) is a quick and well -tolerated procedure to measure the summed 
electric potential of the brain measured at the scalp. Resting- state EEG will be recorded (5 
minutes resting eyes open, 5 minutes resting eyes closed) using a saline- based, high- density 
(≥64 channels) montage.  At sites where EEG is available this procedure will be done prior to 
rTMS/sham treatment and again at approximately week 4.  The week 4 EEG will only be obtained 
for those participants for whom the EEG was conduc ted at randomization.  
 Psychological Assessments  
 Mini International Neuropsychiatric Interview Plus  
The MINI (Sheehan et al., 1998) is a semi -structured interview designed to ascertain a current, 
past, or lifetime history of the major Axis I psychiatric disorders in DSM -IV and ICD -10. Based on 
the original MINI, an expanded version (MINI 7.0.2) has been developed and validated for DSM -
5. The MINI 7.0.2 will be administered (excluding the substance use section) by [CONTACT_847836].  Equivocal diagnoses 
will be confirmed by [CONTACT_847817].  
 Hospi[INVESTIGATOR_5620] (HAD S) 
The HADS (Zigmond & Snaith, 1983) is a brief, validated instrument that screens for both 
depression and anxiety (Bjelland et al., 2002). It will be administered at screening, once during 
weeks 4 and 8 of treatment, at the end of treatment  assessment, and at each follow -up 
assessment. 
 The Pi[INVESTIGATOR_2272] (PSQ I) 
The Pi[INVESTIGATOR_2272] (PSQI; Buysse et al., 1989) will be used to complement 
standard AE assessment of sleep changes. The PSQI is a relatively brief, validated instrument 
that measures sleep quality. The PSQI is designed to be administered every 30 days and will be completed following the schedule outlined in the study timetable.  
 Concise Health Risk Tracking – Participant Rated Module 
(CHRT -SR) Suicidal Behavior Evaluation  
The CHRT -SR (Trivedi et al. , 2011) is a 16 -item participant self-report assessment of suicidality 
and related thoughts and behaviors. The scale is designed to quickly and easily track suicidality 
in a manner consistent with the Columbia Classification Algorithm of Suicide Assessment (C -
CASA) (Posner et al. , 2007). The CHRT- SR will be assessed at screening, every week during the 
treatment phase, at the end- of-treatment assessment, and at the 12 - and 16- week follow -up 
assessments. Responses on the measure will always be reviewed by [CONTACT_847837]-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
50 conclusion. Individuals who report a significant suicidal/homicidal risk, as indicated by a response 
of 2 or greater (Agree or Strongly Agree) on Items 14, 15 or 16 (the final 3 suicidal thoughts items) 
will be assessed by a qualified clinician before leaving the clinic (see the Concise Health Risk Tracking – Clinician Rated measure below).  
 Concise Health Risk Tracking – Clinician Rated Module (CHRT -
CR)  
The CHRT -CR will be performed by [CONTACT_847838] a participant answers any of 
questions 14 -16 on the CHRT- SR as Agree or Strongly agree as described above. This 
assessment will also include, as needed, more comprehensive risk assessment/safety planning 
provisions, as well as potentially hospi[INVESTIGATOR_059], following site- specific hospi[INVESTIGATOR_847798].  
 Substance Use Assessments  
 Timeline Follow- Back (TLFB)  
The Timeline Follow -Back (Sobel & Sobel, 1992) procedure will be used to elicit the participant’s 
self-reported use, quantity, and route of administration of substances at baseline, throughout the 
treatment period, and at end of treatment  and follow -up assessments. At screening, this form will 
be used to assess substance use for the 30 -day period prior to screening. The TLFB will be 
administered throughout the active treatment phase and through the end of the follow- up period 
to document the participant’s s elf-reported use of substances for each day since the previous 
TLFB assessment. We plan to use the TLFB to track self -reported use of all substances. At the 
12- and 16- week post -randomization follow- up, substance use is reported since the last visit . 
 Caffeine Intake  Assessment  
At screening, the Caffeine Intake  Assessment will be modeled after the Supplemental Beverage 
Questions in use for the ABCD Study (Lisdahl et al ., 2018). If a participant endorses use of any 
caffeinated beverages, they are then asked the typi[INVESTIGATOR_847799] 30 -days (covering categories of coffee, espresso, tea with caffeine, soda with 
caffeine, and energy drinks). A briefer version of the Caffeine Intake  Assessment (Daily Caffeine 
Assessment) will be conducted prior to each rTMS/sham session (covering the past 24 -hours) in 
a manner consistent with the FORM -[ADDRESS_1178713]  
The DSM -5 (American Psychiatric Association, 2013) Checklist is a semi -structured, interviewer -
administered instrument that provides current diagnoses for substance use disorders based on 
DSM -[ADDRESS_1178714] 12 months  (including cocaine and methamphetamine).  
 NIDA Cannabis Use Assessment   
This survey assesses participants' recreational and medical cannabis/marijuana use frequency 
over the past 12 months, including reasons for use (e.g., to address medical/psychological 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178715] other substances or medications), method of administration, and perceived 
harm or benefit associated with use. This form will be completed at screening.  
 Fagerström Test for Nicotine Dependence  
The Fagerström Test for Nicotine Dependence (FTND) is used for assessing cigarette use and 
nicotine dependence (Heatherton et al., 1991) and will be administered to each participant at 
screening, at treatment week 4, end of treatment , and at each follow -up. 
 Cue Craving Assessment  
The craving scale will assess  current craving immediately  following cue exposure, as well as after 
each rTMS /sham session. An additional item  assessing ability to resist using  is presented after 
each rTMS /sham session . This assessment will be performed immediately following cue 
presentation and at the end of each rTMS/sham session to make sure the participant is not 
experiencing significant craving before leaving the study site.  
 Daily Assessments  
 Daily Monitoring  
To augment data collection in this trial, we will administer remote assessments/surveys to 
participants on their mobile devices through ePRO . Brief, electronic remote surveys will be 
administered to participants on day 1 of treatment and will occur daily until the week 16 follow -up 
time point (regardless of when the follow -up visit actually occurs). Data collection in- between 
study visits is critical for study outcomes and capturing an accurate pi[INVESTIGATOR_847800]. Remote surveys may also aid in retention of study participants and allow research 
members to more intensively follow- up with participants should they miss a survey (allowing for 
more potential contact [CONTACT_20688]).  
Remote surveys  w
 ill be delivered to the participant’s mobile phone as a survey invite link through 
an SMS text message (and via email). If participants do not have smartphones, one will be 
provided for use during the course of the study. Participants will also have the option to receive 
remote surveys via email. The survey invite  includes an individualized link that contains 
embedded data. Participants will have [ADDRESS_1178716] survey of the day will be retained.  
Two versions of the daily survey will be utilized, based on participant report of their primary s
timulant substance(s) of abuse during screening: (1) primary cocaine; or (2) primary 
methamphetamines. The survey will ask participants to answer whether or not they used their primary reported substance of abuse (Yes/No); to rate their craving using a Visual Analog Scale;  
to rate their ability to resist use of primary substance on a Visual Analog Scale; to rate their overall mood on Visual Analog Scale; and to rate overall sleep quality on a Visual Analog Scale. 
Participants will receive the survey link at the same time each day, and be asked to report on the last 24 hours.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178717] participants’ daily sleep data. 
Information obtained from the device includes, but is not limited to, sleep latency, sleep duration, 
and intervals of waking during the sleep period. Participants will be provided with the device and 
necessary accessories for wear and ba ttery charging. Data will be extracted from the device by 
[CONTACT_847839].  
 Lab Testing And Samples  
 Urine Drug Screen for Other Substances  
To assess the efficacy outcome, Urine Drug Screens (UDS) will be collected at screening, randomization,  at each treatment session prior to beginning the rTMS/sham treatment, at the end 
of treatment  visit and follow- up visits  (UDS will be omitted if follow- up visits are per formed 
remotely) . All urine specimens will be collected using FDA -approved one- step temperature-
controlled urine drug test cups following all of the manufacturer's recommended procedures.  
Urine drug screen (UDS) testing will be performed using a FDA  cleared for use one -step urine 
drug dip card following the manufacturer's recommended procedures. Single dipsticks will be 
used for fentanyl testing.  Fentanyl dipsticks are not FDA cleared, therefore, results cannot be 
used for clinical care. Results can only be used to add to the study database to characterize a 
study population.  The UDS will test for the presence of the following drugs: opi[INVESTIGATOR_2438], oxycodone, 
barbiturates, benzodiazepi[INVESTIGATOR_1651], cocaine, amphetamine, methamphetamine, marijuana, methadone, buprenorphine, phencyclidine (PCP), fentanyl and ecstasy (MDMA). In the event 
urine specimen tampering is suspected, either based on the observation or the adulterant tests, 
research staff should request a second urine sample and may observe the urine collection process according to clinic standard operating procedures. A further validity check is performed 
using a commercially available adulterant test strip. 
 Urine Pregnancy Test  
A urine pregnancy test will be conducted at screening to determine eligibility for study procedures. 
If the test is positive, no further procedures will be conducted, and the participant will be excluded from study procedures.  If screening and randomization do not occu r on the same day, urine 
pregnancy test will be repeated before rand omization procedure.  Additional urine pregnancy tests 
will be administered prior to the first visit of treatment week 4 and treatment week 8. If positive, women will no longer receive the rTMS intervention. Pregnancy will be followed through resolution.  Women will need to agree to use an ap propriate form of birth control throughout the 
treatment phase of the study.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178718] matter experts, as applicable.  Remote training will be conducted 
as possible, including training in rTMS and EEG monitoring  (where applicable) .  
The CTN -0108 research staff will be trained as specified in the study Training Plan. Training will 
include Human Subjects Protection (HSP) and Good Clinical Practice (GCP) as well as protocol -
specific training on assessments, study interventions, safety and safety event reporti ng, study 
visits and procedures, data management, quality assurance, laboratory procedures, etc. The 
Lead Node is primarily responsible for development and delivery of study -specific training related 
to the study intervention(s) and procedures. The CCC is responsible for the development and delivery of non -intervention training, including regulatory and laboratory procedures, safety and 
safety event reporting, quality assurance and monitoring, etc. The DSC is responsible for training related to data management (DM), the electronic data capture system, and good clinical DM 
practices. Other parties will contribute as needed based on the subject matter and material to be covered. The various sub- teams will collaborate to deliver quality instructional material designed 
to prepare research staff to fully perform study procedures based on the assigned research roles 
and responsibilities.  
In addition to general and study -specific training, the Training Plan will include a description of 
the delivery methods to be used for each training module (e.g., via self -study, online, webcast, or 
teleconference). Research staff are required to complete institutionally required training per  their 
research site, Institutional Review Board(s), and authorities with regulatory oversight. Tracking of training completion for individual staff as prescribed for assigned study role(s) will be documented, 
endorsed by [CONTACT_1377] [INVESTIGATOR_268507], and audited by [CONTACT_145859]. As changes occur in the prescribed training, the Training Plan and training documentation tracking 
forms will be amended to reflect these adjustments.  
 rTMS Training and Supervision  
All site s must have experience in the delivery of rTMS. Site Operating Procedures ( SOPs ) for the 
use of the MagVenture MagPro X100 system  and the Provider Manual will be provided to research 
staff. Training will be provided for study -specific rTMS procedures  by [CONTACT_847840]. Additionally , rTMS  Operators , rTMS 
Advanced Operators,  and Site PI s will be  trained by [CONTACT_847841] a MagVenture Certification of Completion. At each site, the 
Medical Clinician  will supervise  (as defin ed in the MOP)  the rTMS delivery.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
54 14.0 CONCOMITANT THERAPY /INTERVENTION 
 General  
Individuals are not allowed to engage in any other treatments specifically targeting their substance 
use disorder, other than the study provided CBT app,  because this could interfere with the ability 
to detect the effect of r TMS . Study participants  may engage  only in self -help group activities  (e.g., 
Alcoholics Anonymous, Narcotics Anonymous, SMART Recovery) focused on their substance 
use disorder . However, participants may engage in treatments targeting other psychiatric 
disorders.  
 Medications Prohibited/Allowed During Trial  
Anticonvulsants  and/or benzodiazepi[INVESTIGATOR_847801] . Participants who are prescribed anticonvulsants or benzodiazepi[INVESTIGATOR_847802] a stable dose for at least [ADDRESS_1178719] medical assessments (see Table 5 in Section 12) at screening, each treatment session, 
end of treatment  visit (if applicable), as well as 12 - and 16- week follow -up visits.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
55 15.0 STATISTICAL DESIGN AND ANALYSE S 
 General Design  
 Study Hypothes es 
The primary hypothes is for this trial  relates to feasibility :  
Primary (Feasibility) Hypothesis : More than 75% of all participants randomized in CTN -0108 
will receive 20 or more rTMS sessions.  
The secondary hypothesis for this trial relates to efficacy . It is stated separately  for MUD and CUD 
for clarity.  
Secondary (Efficacy , CUD ) Hypothesis: Individuals who enroll with primary CUD and receive 
active rTMS will have a significantly higher percentage of weekly  negative  UDS  results over the 
course of treatment, as compared to those in the sham group.  
Secondary (Efficacy, MUD) Hypothesis: Individuals who enroll with primary M UD and receive 
active rTMS will have a significantly higher percentage of weekly negative  UDS  results over the 
course of treatment, as compared to those in the sham group. 
 Primary and Secondary Outcomes (Endpoints)  
The primary (feasibility ) outcome measure is the percentage of participants  who obtain at least 
20 rTMS treatment sessions over the 8- week treatment period. The primary outcome  measure 
does not consider whether a participant was randomized with CUD or MUD.  
The secondary ( efficacy) outcome measure  for each participant  is the number and percent of 
weekly negative UDS results over the treatment peri od. The last UDS collected in a study week 
is used for that week.  A UDS will be considered as negative for participants with primary CUD if 
it indicates no cocaine use. A UDS will be considered as negative for participants with primary 
MUD if it indicates no methamphetamine use.  
Exploratory outcomes may include, and are not limited to: 
• Other feasibility measures:  
o Percent of participants that complete at least 75% of daily monitoring  
o Percent of participants that complete all follow -up visits  
• Self-reported cocaine and methamphetamine use (Timeline Follow -Back) 
• Cocaine and/or methamphetamine craving (VAS)  
• Depression/anxiety symptoms (Hospi[INVESTIGATOR_5620])  
• Sleep quality (Actigraphy, Pi[INVESTIGATOR_2272]) 
• Quality of life ( HRQOL -4 quality of life assessment ) 
• Impact of personal characteristics (age, handedness) on treatment outcomes  
• CBT participation  
• Motor threshold changes over the treatment course 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
56 
 Recruitment  
A total of approximately 160 individuals with moderate to severe cocaine ( approximately N=80) 
and methamphetamine ( approximately N=80) use disorder who have an interest in cutting down 
or stoppi[INVESTIGATOR_847803] ( up to 80 participants  per site; no more than 160 participants 
total). This sample size provides  adequately sized 95% confidence intervals  for the primary 
outcome  and greater than 80% power to detect medium -sized effect size s, measured as odds 
ratios,  of greater than [ADDRESS_1178720] and significance level of 0.05  for the 
secondary (efficacy) outcome for both CUD and MUD . 
 Randomization and Factors for Stratification  
Randomization will be stratified based on  study site , MDE,  and whether the participant enters on 
primary CUD or MUD. The sample size within each of CUD an d MUD is assumed to be 80.  
Following determination of full study eligibility via screening, and completion of baseline 
assessments, participants will be randomly assigned to one of the two conditions (rTMS or sham) for 8 weeks of treatment. Random assignment will be on a 1:1 ratio to one of the two conditions. 
Randomization will be stratified by [CONTACT_3885] , MDE,  and CUD or MUD primary group designation . 
The randomization procedure will be conducted centrally through the CTN DSC, and randomization assignments will not be conveyed to research staff (including rTMS  Operator s) or 
participants. The DSC statistician will generate the randomization schedule using balanced blocks 
of varying sizes within strata to ensure lack of predictability along with relative equality of 
assignments across treatment groups. The DSC statistician will review randomization data on a regular basis to ensure that the scheme is being implemented according to plan. A randomization 
slot, once used, will not be re -allocated due to the intent -to-treat nature of the study. 
 Rationale For Sample Size and Statistical Power  
The rationale for the sample size is broken into two parts:  precision analysis for the primary 
(feasibility ) outcome and typi[INVESTIGATOR_847804] y (efficacy) outcome.  
 Precision Analysis  
A simulation study was conducted where a dataset with a sample size of 160 was generated 
where each participant had a binary feasibility outcome generated from a Bernoulli distribution 
with 𝑝𝑝= 0.75 because the goal rate for the outcome is 75%. The 95% confidence interval 
halfwidth was then calculated using the Wilson method. This process was repeated 100,000 
times. The average 95% confidence interval halfwidth was calculated across the 100,000 
simulated datasets.  
Also considered in the simulation study w ere different sample sizes and proportion used for 
generating the binary outcome. Different sample sizes (40, 80, 120, 160, 200, 400) were included 
to gauge the effect of decreased and increased sample sizes on 95% confidence interval 
halfwidths as an increase in sample size does not have a constant effect on halfwidth. Different 
proportions (0.5, 0.6, 0.75) were considered for generating the binary outcome because, generally, as a proportion approaches 0.5 or 50% the variability increases. An increase in 
variability directly increases confidence interval halfwidth.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
57 Results are presented in the table and graph below. At a sample size of 160 and a proportion of 
0.75 (75%), the average 95% confidence interval halfwidth is approximately 0.066. That is, the 
95% confidence interval would have about 6.6% on each site. For example, a confidence interval 
in this setting would look something like 𝑝𝑝̂ −0.066 to 𝑝𝑝̂+ 0.066 where 𝑝𝑝̂ is whatever the estimate 
percentage is. The halfwidth increased up to only 7.6% for the sample size of 160 when a 
proportion of 0.5 was used. Only relatively marginal decreases in halfwidth occurred up to a sample size of 400. A total sample size of 160 is considered appropriate for this study.  
Table 7: Confidence Interval Halfwidth for Primary (Feasibility) Outcome  
 
 Feasibility Metric 
Assumption (%)  Total 
Sample Size  Average 95% 
Confidence 
Interval Halfwidth  
50% 40 0.146  
80 0.106  
120 0.088  
160 0.076  
200 0.068  
400 0.049  
60% 40 0.144  
80 0.104  
120 0.086  
160 0.075  
200 0.067  
400 0.048  
75% 40 0.128  
80 0.093  
120 0.076  
160 0.066  
200 0.059  
400 0.042  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
58 Figure 2: Plot of Confidence Interval Halfwidth by [CONTACT_847842] (Feasibility) Outcome  
 
 Power Analysis  
Similarly, power analysis via simulation studies was conducted for the secondary ( efficacy) 
outcome. Since participants enrolled with cocaine use disorder and participants enrolled with 
methamphetamine use disorder  are analyzed separately, a sample size of 80 is used. Participants 
randomly assigned to receive the sham rTMS had their number of negative UDS generated from a binomial distribution with n = 8 and p = 0.36 . The probability of 0.36 for a negative UDS was  
based on the results found in Terraneo et al. (2016) when comparing rTMS to control on cocaine 
use. They found, at baseline, an average of  about  4.5 use days per week. This would mean then 
that there’s roughly 4. 5/7 = 0.[ADDRESS_1178721] 3 days, which may mean that 
true probability of negative UDS may be less than 0.36, a proportion further from 0.5 (holding all 
else constant) would generally result in higher power. Therefore, the use 0.[ADDRESS_1178722] been found. Participants  randomly assigned to real rTMS had their number of negative UDS 
generated from  a binomial distribution with  n = [ADDRESS_1178723] 
sized used. In the same paper by [CONTACT_847843] . (2016) , they found roughly a 6.5 odds ratio (OR) 
for any use. The power analyses performed here considers a few lower , more conservative,  odds 
ratio levels  of 2, 3, 4, and 5. This includes the clinically meaningful odds ratio of 2. In order to 
match the model to be fit  and to allow correlation between UDS from the same participant , a 

NIDA CTN-0108   Version 7.0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178724] deviation used was determined based on a small set of possible within- participant 
correlation, or intraclass correlation (ICC),  values . Specifically, ICCs of 0.[ADDRESS_1178725] logistic regression model was fit with only binary 
treatment (1 for real rTMS) , binary stratum, week,  and site as fixed effects and a random effect to 
account for correlation between UDS from the same participant . Each weekly UDS enters the 
model as a binary response.  If the model estimation procedure had issues with not being positive 
definite, the model was refit with the random effect removed.  Once the model was fit, it was 
determined whether the treatment covariate was significant or not at the 0.05 confidence level (i.e., if the p -value was less than 0.05). If the covariate was significant, the treatment effect was 
considered significant. This process, along with data generation, was repeated [ADDRESS_1178726] 80% was desired.  
The power to detect a significant treatment effect decreases as treatment effect size and sample 
size decrease. To this end, the simulation study also considered other sample sizes (40, 60, and 
100) and different treatment effect sizes, with the highest  odds ratio  being [ADDRESS_1178727] being 
2, a clinically meaningful level . Note that this range of odds ratios is below the estimate found in 
Terraneo et al . (2016) , (of 6.5)  for a similar outcome . As previously mentioned, differing 
proportions in the sham rTMS arm are also considered to gauge the sensitivity of the results to 
the assumption of 0.[ADDRESS_1178728] is classified 
based on Cohen’s h (Cohen 1988)  as medium . With the assumption of a 0.36 ba seline probability 
in the sham rTMS group, regardless of the ICC  used, a sample size of 80 shows power of 80% 
or greater for an odds ratio of at least 4. That is , it achieves greater than 80% power at an odds 
ratio of 4, well below the effect size Terreneo et al found for a similar outcome. A clinically 
meaningful odds ratio of 2 does not reach 80% power at any considered sample size, including 
100, under any scenario.  The results do not appear to be overly sensitive to the assumption of a 
0.[ADDRESS_1178729] 5 when the ICC is 0.5. While this study isn’t directly powered for 
efficacy, the results presented here show that a sample size of 80 allows greater than 80% power 
to detect a significant treatment difference at reasonable, medium -sized,  treatment effect s (lower 
than found in a similar study with a similar outcome) , is relatively robust to assumptions made in 
the pow er analysis , and the use of a sample size of 80 for both MUD and CUD is , therefore , 
reasonable.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
60 Table 8: Power Analysis Results for Secondary (Efficacy) Outcome  
 
 Power  
ICC Baseline Probability  Odds Ratio  Treatment Effect Size  N = 40  N = 60  N = 80  N = [ADDRESS_1178730]  41% 53% 66% 75% 
3.0 77% 90% 96% 99% 
4.0 92% 99% 100%  100%  
5.0 97% 100%  100%  100%  
0.[ADDRESS_1178731]  43% 56% 67% 75% 
3.0 78% 90% 96% 99% 
4.0 92% 98% 100%  100%  
5.0 97% 100%  100%  100%  
0.[ADDRESS_1178732]  43% 55% 67% 76% 
3.0 77% 90% 96% 99% 
4.0 91% 98% 100%  100%  
5.0 97% 100%  100%  100%  
0.[ADDRESS_1178733]  22% 27% 33% 40% 
3.0 43% 57% 67% 77% 
4.0 60% 75% 86% 92% 
5.0 72% 86% 94% 97% 
0.[ADDRESS_1178734]  23% 29% 35% 42% 
3.0 43% 58% 69% 77% 
4.0 60% 75% 86% 92% 
5.0 72% 86% 94% 97% 
0.[ADDRESS_1178735]  22% 28% 33% 41% 
3.0 43% 55% 67% 76% 
4.0 59% 75% 86% 92% 
5.0 71% 85% 94% 97% 
 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
61 Figure  3: Plot of Power by [CONTACT_847844] (Efficacy) Outcome  
 
 Projected Number of Sites   
Four study sites will participate in the study.  
 Projected Number of Participants per Site  
Each study site will enroll approximately 40 (20 for each of CUD and MUD)  participants, with the 
goal of randomizing approximately  160 (80 for each of CUD and MUD)  participants across the 4 
study sites.  
 Statistical Methods f or Primary a nd Secondary Outcomes  
 Primary  (Feasibility)  Outcome  
The primary feasibility outcome of the percentage of participants who receive 20 or more rTMS 
sessions will be summarized by [CONTACT_847845] a 95% confidence interval by [CONTACT_847846]. This method was chosen over others, including an exact  or Clopper -Pearson 
method because the Wilson method has shown to have better performance than exact or Wald 
methods (Brown et al ., 2001.). There is no hypothesis testing. The corresponding shell SAS code 
is provided below.  
proc freq data = dat; 
     table y / binomial(cl = wilson); 
run; 
y i s the binary variable indicating whether the participant received at least 20 rTMS treatment sessions. 

NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
62 
 Secondary (Efficacy) Outcome  
The secondary ( efficacy ) outcome will be analyzed with a generalized linear mixed model  
approach to adjust for correlation between UDS from the same participants  and to provide 
conditional interpretation of the treatment effect . The model will include fixed effects for treatment , 
MDE, week, and site and a random effect for participant . It is important to note that a binary 
response of negative UDS, for each UDS provided by [CONTACT_32659], will be used as the 
outcome as opposed to just their percentage of negative UDS. The model  used still allows 
inference on the overall probably of a negative weekly UDS during the treatment period. 
Additionally, week will enter the model as a categorical variable to allow greater flexibility on the 
effect of week.  
The assessment of the significance of the treatment will be done by [CONTACT_847847] 0.[ADDRESS_1178736] will be measured by [CONTACT_847848] 95% confidence interval. The corresponding shell SAS code is 
provided below.  
proc glimmix data = dat method = quad;  
     class site week participant;  
     model y(event = ‘1’) = trt mde week site / dist = binary link 
= logit; 
     random intercept / subject = participant;  
run; 
dat i s a dataset with one row per weekly UDS per participant. y is the a binary variable with a 
value of [ADDRESS_1178737] for the correlation within participant. This is 
accomplished simply by [CONTACT_847849].  
An odds ratio (as the exponential of the trt coefficient), along with 95% confidence interval, will be 
provided to assess the effect of treatment. An odds ratio of greater than [ADDRESS_1178738].  
The model and results will be conducted and presented separately for those participants 
randomized with CUD or MUD. 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
63 
 Significance Testing  
The secondary (efficacy) outcome will be evaluated using a two -sided test on the significance of 
the treatment parameter in the proposed model with a type I error rate of 5%.  No attempt will be 
made to control family -wise type I error rate when testing for CUD and MUD participants.  No other 
hypothesis testing will be performed on the primary or secondary outcomes. 
 Types of Analyses  
 Additional Feasibility Analysis  
The primary analysis method used for the primary (feasibility ) outcome will be completed over all 
160 participants. Additional analysis may include estimating the feasibility outcome percentage 
separately for both CUD and MUD participants, separately for real and sham rTMS, as well as 
separately for the four combinations of the two factors. Testing may be performed using fisher’s 
exact test at an 0.05 significance level to determine if there are differences in the percentages across or within the factors, though emphasis is placed on estimation and 95% confidence 
intervals. 
 Additional Efficacy Analysis  
In preparation to assist in designing future larger trials of efficacy, estimates of the MDE, site and 
participant effects may be explicitly given. For the participant effect, t his will likely be an estimate 
of the variance in the outcome attributed to the within participant correlation . 
Additional supportive analysis of the secondary (efficacy) outcome will be examining if treatment 
effect varies depending on study week. This can be accomplished by [CONTACT_847850]. If significant, estimates of treatment effect based on study week 
can be presented.  
 Interim Analysis  
A DSMB will monitor the progress of the trial. No classical interim analyses relating to futility or sample size re- estimation will be implemented in this pi[INVESTIGATOR_799].  Safety halting rules are 
presented in the Study Halting Rules section elsewhere in the protocol.  
 Exploratory Analysis  
Recall the exploratory outcomes  may include, and are not limited to  
• Other feasibility measures:  
o Percent of participants that complete at least 75% of daily monitoring  
o Percent of participants that complete all follow -up visits  
• Self-reported cocaine and methamphetamine use (Timeline Follow -Back) 
• Cocaine and/or methamphetamine craving (VAS)  
• Depression/anxiety symptoms (Hospi[INVESTIGATOR_5620])  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
64 • Sleep quality (Actigraphy, Pi[INVESTIGATOR_2272]) 
• Quality of life ( HRQOL -4 quality of life assessment ) 
• Resting connectome biomarkers measured by [CONTACT_66594] 
• Differences in outcomes based on number of CBT sessions completed  
• Impact of handedness on treatment outcome  
• Impact of changes in motor threshold over treatment course on treatment outcome  
The other feasibility measures may be analyzed analogously  to the primary (feasibility) outcome . 
The other exploratory outcomes may be summarized and analyzed as appropriate for the type of 
outcome, such as fisher exact tests and/or logistic regression models for binary outcomes and 
non-parametric tests of mean/median differences and other types of regression models for ordinal 
or continuous outcomes.  
 Missing Data and Dropouts  
As defined, the primary (feasibility ) outcome will have no missing data . Participants that drop out 
early will still be evaluated as to whether they attended at least 20 rTMS sessions.  
The secondary (efficacy) outcome is expected to have missing data , specifically UDS results . The 
proposed analysis model takes into account all available data and missing data are assumed to 
be missing at random ( a weaker assumption than missing completely at random ). That is, 
missingness  is allowed to depend on observed covariates. As such, the prespecified analysis 
method does not need missing  data to be imputed or handled in some special way.  That being 
said, alternative methods of handling missing data may be considered as sensitivity analyses. 
Some specific examples may involve imputing a negative UDS in place of missing if that UDS is 
immediately surrounded by [CONTACT_847851], imputing missing UDS results based on self -reported 
use, or imputing all missing UDS as positive. More technical methods incorporating a missing not 
at random assumption may also be considered. 
 Demographic and Baseline Characteristics 
Baseline demographic and clinical variables will be summarized for participants enrolled in the 
active medication phase of the trial. Descriptive summaries of the distribution of continuous baseline variables will be presented with percentiles (median, 25th and 75th percentiles), and with mean and standard deviation. Categorical variables will be summarized in terms of ‘ frequencies 
and percentages.  
 Subgroup Analyses  
Per NIH policy, subgroup analyses will be implemented to assess whether sex, race, and/or ethnicity are feasibility or effect modifiers. The primary outcome percentage will be estimated in each demographic subgroup. The secondary (efficacy) outcome results  will be presented and 
tested (as applicable) within each demographic subgroup by [CONTACT_268628].  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
65 
 Safety Analysis  
AEs, SAEs  and UADEs , will be summarized by [CONTACT_556189] (per The Medical Dictionary for Regulatory Activities). AEs will be presented as: (1) the 
number and proportion of participants experiencing at least one incidence of each event overall; 
and (2) the total number of each event overall in tabular form. Listings of SAEs  /UADEs  will be 
sorted by  [CONTACT_9313] (SOC) , and preferred term  (PT). Detail in these listings will include 
severity, relationship to study medication(s), and action taken, as available. 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178739] to the abbreviated IDE regulations  as 
stated in 21 CFR 812.2(b). The Sponsor will obtain and maintain IRB approval  accordingly , and 
will be subject to all applicable reporting requirements.  
 Statement of Compliance  
This trial will be conducted in accordance with the current version of the protocol, in full conformity 
with the ethical principles outlined in the Declaration of Helsinki, the Protection of Human Subjects described in the International Council for Harmonisation Good Clinical Practice (GCP) Guidelines, applicable [LOCATION_002] (US) Code of Federal Regulations (CFR), the NIDA Terms and Conditions of Award, and all other applicable state, local, and federal regulatory requirements. 
The Principal Investigator [INVESTIGATOR_7433], or changes to the protocol will take 
place without prior agreement from the Sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the tri al 
participants. An Operations Manual will be provided as a reference guide and study quality 
assurance tool.  
 Institutional Review Board Approval  
This study will utilize a single IRB  (sIRB) . Prior to initiating the study, site investigators will obtain 
permission to rely on the MUSC IRB from their  local IRB s. Local IRBs will enter into a reliance 
agreement with MUSC. Each participating site must have sIRB  approval prior to conducting the 
study. Should changes to the study protocol become necessary, protocol amendments will be 
submitted in writing by [CONTACT_847852]. In 
addition, the sIRB  will approve all consent forms, and recruitment materials, and any study -
specific materials given to the participant. Annual progress reports will be submitted to the sIRB 
annually or at a frequency requested so that continuous study approval is maintained without 
lapse. The lead investigator is responsible for maintaining in his research files copi[INVESTIGATOR_847805](s) current IRB/IEC approval notice(s), IRB -approved consent document(s), 
including approval for all protocol modifications. The lead site will submit regulatory documents to the sIRB on behalf of the participating sites.  Participating sites will receive electronic notifications 
of approval or changes required directly from the sIRB. The lead team will also have access to all 
of these documents . 
Prior to initiating the study, participating site investigators will obtain written approval from the 
single  Institutional Review Board ( sIRB) of record to conduct the study at their respective site, 
which will include approval of the study protocol. Approval of both the protocol and the consent form(s) must be obtained before any participant is consented. For changes to the consent form, a decision will b e made regarding whether previously consented participants need to be re -
consented. IRB continuing review will be performed annually, or at a greater frequency contingent 
upon the complexity and risk of the study. Each site principal investigator [INVESTIGATOR_847806]-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178740], and will enter into 
reliance/authorization agreements for Protocol CTN -0108. MUSC Institutional Review Board will 
follow written procedures for reporting its findings and actions to appropriate officials at each participating institution. Some sites may meet Exception Criteria to the NIH sIRB Policy and may not utilize the IRB of Record.  
 Informed Consent  
The informed consent process is a means of providing study information to each prospective 
participant and allows for an informed decision about participation in the study. Informed consent continues throughout the individual’s study participation. The informed consent form(s) will include 
all of the required elements of informed consent, and may contain additional relevant consent 
elements and NIDA CCTN specific additional elements. Each study site must have the study informed consent(s) approved by [CONTACT_847853]. Prior to initial submission to the IRB and with each 
subsequent consent revision, the consent form(s) must be sent to the Clinical Coordinating Center 
(CCC) to confirm that each consent form contains the required elements of informed consent as 
delineated in 21 CFR 50.25(a) and CFR 46.116(b), as well as pertinent additional elements 
detailed in 21 CFR 50.25(b) and 45 CFR 46.116(c) and any applicable CCTN requirements.  Every 
study participant is required to sign a valid, IRB -approved current version of the study informed 
consent form prior to the initiation of any study related procedures.  The site must maintain the 
original signed informed consent for every participant in a locked, secure location that is in compliance with the sIRB  and that is accessible to the study monitors. Every study participant 
should be given a copy of the signed consent form. 
During the informed consent process, research staff will explain the study to the potential 
participant and provide the potential participant with a copy of the consent form to read and keep for reference. All participants will receive a verbal explanation in terms suited to their 
comprehension of the purposes, procedures, and potential risks of the study and their rights as 
research participants. Extensive discussion of risks and possible benefits will be provided to the 
participants. Participants will have the opportunity to carefully review the written consent form and ask questions prior to signing. The participants should have the opportunity to discuss the study with their family and close friends or think about it prior to agreeing to participate. If the participant is interested in participating in the study, a qualified staff member will review each section of the 
IRB-approved informed consent form in detail and answer any questions the participant may 
pose. The participant will consent by [CONTACT_200874]. The person 
obtaining consent will also sign and date the consent document. It is strongly recommended that another research staff member review the consent after it is signed to ensure that the consent is 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178741] participants’ 
participation in the trial. The rights and welfare of the participants will be protected by [CONTACT_34693]. The participant will be informed that their participation is voluntary , and 
they may withdraw from t he study at any time, for any reason without penalty. Individuals who 
refuse to participate or who withdraw from the study will be treated without prejudice. Study sites will be responsible for maintaining signed consent forms as source documents for quali ty 
assurance review and regulatory compliance. 
 Quality Assurance Monitoring 
In accordance with federal regulations, the study sponsor is responsible for ensuring proper monitoring of an investigation and ensuring that the investigation is conducted in accordance with 
the protocol. Qualified monitors will oversee aspects of site conformity to make certain the site 
staff is operating within the confines of the protocol, and in accordance with GCP. This includes but is not limited to protocol compliance, documentation auditing, and ensuring the informed consent process is being correctly followed and documented. Non -conformity with protocol and 
federal regulations will be reported as a protocol deviation and submitted to the study sponsor 
and study IRB of record, (as applicable), for further review.  
 Participant and Data Confidentiality  
Participant confidentiality and privacy are strictly held in trust by [CONTACT_3486], 
their staff, the safety and oversight monitor(s), and the sponsor(s) and funding agency, and will be maintained in accordance with all applicable federal  regulations and/or state/Commonwealth 
law and regulations. This confidentiality is extended to the data being collected as part of this study. Data that could be used to identify a specific study participant will be held in strict confidence within the research team. No personally -identifiable information from the study will be 
released to any unauthorized third party without prior written approval of the sponsor/funding 
agency and the participant. All research activities will be conducted in as private a setting as 
possible.  
The study monitor, other authorized representatives of the sponsor or funding agency, representatives of the Institutional Review Board (IRB), regulatory agencies, may inspect all 
documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) for the participants in this study. The clinical study site 
will permit access to such records.  
Participant records will be held confidential by [CONTACT_9909], secure storage of any documents that have participant identifiers, and secure 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
69 computing procedures for entering and transferring electronic data. The study participant’s 
contact [CONTACT_10414]. 
At the end of the study, all records will continue to be kept in a secure location for as long a period as denoted in Section 16.12 , Records Retention and Requirements.  
By [CONTACT_200877], the investigator affirms that information furnished to the investigator by [CONTACT_200878]/Privacy Board, Ethical Review Committee, or similar ex pert committee; affiliated institution; 
and employees only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees.  
 Certificate of Confidentiality  
To further protect the privacy of study participants, the Secretary, Health and Human Services (HHS), has issued a Certificate of Confidentiality (CoC) to all researchers engaged in biomedical, 
behavioral, clinical or other human subjects research funded wholly or in part by [CONTACT_48160]. Recipi[INVESTIGATOR_240553] (see https://humansubjects.nih.gov/coc/index ). This protects participants from disclosure of sensitive 
information (e.g., drug use).  It is the NIH policy that investigators and others who have access to 
research records will not disclose identifying information except when the participant consents or in certain instances when federal, state, or local law or regulation requires disclosure. NIH expects investigators to inform research participants of the protections and the limits to protections 
provided by a Certificate issued by [CONTACT_17355].  
 Health Insurance Portability  and Accountability Act (HIPAA)  
Study sites may be required by [CONTACT_268637]. Sites will be responsible for communicating with the IR B(s) or 
Privacy Board(s) of record and obtaining the appropriate approvals or waivers to be in regulatory compliance. Releases of participant identifying information that are permitted by [CONTACT_362571], but which are prohibited by [CONTACT_9912]/or state/Commonwealth law and regulation, are prohibited.  
 Investigator Assurances  
Each site must have on file an active Federalwide Assurance (FWA) with the HHS Office for 
Human Research Protection setting forth the commitment of the organization to establish 
appropriate policies and procedures for the protection of human research subjects in alignment 
with 45 CFR 46, Subpart A, with documentation sent to NIDA or its designee. Research covered by [CONTACT_847854] (45 CFR 46.103). Prior to initiating the study, the principal investigator [INVESTIGATOR_200761] a protocol 
signature [CONTACT_362580], providing assurances that the study will be performed according t o the standards stipulated therein. 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178742] monitors who will examine whether study 
procedures are conducted appropriately,  and that study data are generated, documented and 
reported in compliance with the protocol, GCP, and applicable regulations. These monitors will 
audit, at mutually agreed upon times, regulatory documents, case report forms (CRFs), informed 
consent forms and corresponding source documents for each participant. Monitors will have the 
opportunity and ability to review any study -associated document or file.  
NIDA -contracted monitors will assess whether submitted data are accurate and in agreement with 
source documentation and will also review regulatory/essential documents such as 
correspondence with the IRB. Areas of particular concern will be participant informed consent forms, protocol adherence, reported safety events and corresponding assessments, and principal investigator [INVESTIGATOR_200762]. Reports will be prepared following the visit and 
forwarded to the site principal investigator,  the Lead Investigator and NIDA CCTN.  
Qualified node personnel (Node QA monitors) will provide site management for each site during 
the trial. Node QA staff will audit source documentation, including informed consent forms and 
HIPAA forms. This will take place as specified by [CONTACT_9920], node PI [INVESTIGATOR_847807], detect, and correct problems at the study sites. Node QA personnel will verify that study procedures are properly followed and that site personnel are trained and able to conduct the protocol appropriately. If the node personnel’s review of study 
documentation indicates that additional training of site study personnel is needed, node QA 
personnel will undertake or arrange for that training. Details of the contract, node QA and data 
monitoring are found in the study QA monitoring plan.  
 Inclusion of Women and Minorities  
The study sites should aim and take steps to enroll a diverse study population. If difficulty is 
encountered in recruiting an adequate number of women and/or minorities, the difficulties involved in recruitment will be discussed in national conference calls and/or face- to-face meetings, 
encouraging such strategies as linkages with medical sites and /or treatment programs that serve 
a large number of women and/or minorities, advertising in newspapers or radio stations with a high female/minority readership/lis tening audience, etc.  
 Prisoner Certification  
As per 45 CFR 46 Subpart C, there are additional protections pertaining to prisoners as study 
participants. A prisoner is defined as any individual involuntarily confined or detained in a penal institution. The term is intended to encompass individuals sentenced to such an institution under a criminal or civil statute, individuals detained in other facilities by [CONTACT_847855]-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178743] promptly notify the IRB of this occurrence.  
 Regulatory Files  
The regulatory files should contain all required regulatory documents, study -specific documents, 
and all important communications. Regulatory files will be checked at each participating site for regulatory document compliance prior to study initiation, throughout the study, as well as at study 
closure.  
 Records Retention and Requirements  
Research records for all study participants (e.g., case report forms, source documents, signed 
consent forms, audio and video recordings, and regulatory files) are to be maintained by [CONTACT_9916] a secure location for a minimum of [ADDRESS_1178744] or outcome of the trial or increase risk to study participants. AE, 
SAE, and UADE reporting will occur as previously described. At the completion of the trial, the 
Lead Investigator will provide a final report to the Sponsor.  
 Audits  
The Sponsor has an obligation to ensure that this trial is conducted according to good clinical  
research practice guidelines and may perform quality assurance audits for protocol compliance. 
The Lead Investigator and authorized staff from the Southern Consortium  Node; the National 
Institute on Drug Abuse Clinical Trials Network (NIDA CTN, the study sponsor); NIDA’s contracted agents, monitors or auditors; and other agencies such as the Department of Health and Human Services (HHS), the Office for Human Research Protection (OHRP) and the sites’ Institutional 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178745] research records for verification of data, compliance with federal 
guidelines on human participant research, and to assess participant safety.  
 Study Documentation 
Each participating site will maintain appropriate study documentation (including medical and 
research records) for this trial, in compliance with ICH E6 R2 and regulatory and institutional requirements for the protection of confidentiality of participants.  Study documentation includes all 
case report forms, workbooks, source documents, monitoring logs and appointment schedules, sponsor -investigator correspondence, and signed protocol and amendments, Ethics Review 
Committee or Institutional Review Board correspondence and approved consent form and signed participant consent forms. As part of participating in a NIDA -sponsored study, each site will permit 
authorized representatives from NIDA and regulatory agencies to examine (and when permitted by [CONTACT_2371], to copy) clinical records for the purposes of quality assurance reviews, audits, and 
evaluation of the study safety, progress, and data validity. 
Source documents include a
 ll recordings of observations or notations of clinical activities and all 
reports and records necessary for the evaluation and reconstruction of the clinical research study. 
Whenever possible, the original recording of an observation should be retained as the source 
document; however, a photocopy is acceptable provided that it is a clear, legible, and exact duplication of the original document.  
 Protocol Deviations  
This protocol defines a protocol deviation as any noncompliance with the clinical trial protocol. 
The noncompliance may be either on the part of the participant, the investigator, or the research 
site staff. As a result of deviations, corrective actions will be developed by [CONTACT_90478].  
These practices are consistent with ICH GCP:  
1. Section 4.5 Compliance with Protocol, subsections 4.5.1, 4.5.2, and 4.5.3  
2. Section 5.1 Quality Assurance and Quality Control, subsection 5.1.1  
3. Section 5.20 Noncompliance, subsections 5.20.1, and 5.20.2.  
Any departure from procedures and requirements outlined in the protocol will be classified as 
either a major or minor protocol deviation. The difference between a major and minor protocol deviation has to do with the seriousness of the event and the corrective action required. A minor 
protocol deviation is considered an action (or inaction) that by [CONTACT_200884], rights, or welfare of a study participant. Major pro tocol deviations are departures that may compromise the participant safety, 
participant rights, inclusion/exclusion criteria or the integrity of study data and could be cause for corrective actions if not rectified or prevented from re- occurrence. Sites wi ll be responsible for 
developi[INVESTIGATOR_9818]. Those corrective action plans may be reviewed/approved by [CONTACT_847856]. All protocol deviations will be monitored at each site for 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
73 (1) significance, (2) frequency, and (3) impact on the study objectives, to ensure that site 
performance does not compromise the integrity of the trial.  
All protocol deviations will be recorded in the Electronic Data Capture (EDC) system via the 
Protocol Deviation CRF. The CCC, DSC and the Lead Investigator must be contact[CONTACT_200886].  
Additionally, each site is responsible for reviewing the s IRB’s  definition of a protocol deviation or 
violation and understanding which events need to be reported. Sites must recognize that the CTN 
and sIRB definition of a reportable event may differ and act accordingly in following all reporting 
requirements for both entities.  
 Safety Monitoring  
Each participating site will have a  site Medical Clinician (MD, DO, NP, or PA) for this study, who 
will review or provide consultation for each Adverse Event (AE) , Serious Adverse Event (SAE)  
and Unanticipated Adverse Device Effects (UADE)  as needed. These reviews will include an 
assessment of the possible relatedness of the event to the study intervention or other study 
procedures. The Site Medical Clinician will also provide advice for decisions to exclude, refer, or 
withdraw participants  as required. In addition, NIDA will assign a Safety Monitor/Medical Monitor 
to this protocol to independently review the safety data  from this study and  present it to the DSMB 
for periodic review. The Safety Monitor/Medical Monitor will determine which safety events require 
expedited reporting to NIDA , the DSMB and/or  regulatory authorities  (i.e., reported to the IRB for 
an abbreviated IDE as regulated under 21 CFR 812) . This will include all UADE s, which is defined 
as any serious adverse effect, any life -threatening problem or death caused by, or associated 
with a device, if that was not previously identified in the application; or any other unanticipated serious problem associated with a device. The site research staff will be trained to monitor AEs , 
SAEs  and UADEs . The site Medical Clinician and the Safety Monitor/Medical Monitor will 
collaborate to evaluate the effect and to determine its reportability . All SAEs are reported into 
Advantage eClinical
SM within 24 hours of awareness. If an UADE is identified, the site Medical 
Clinician /Principal Investigator  [INVESTIGATOR_847808], but in no event 
later than 10 working days after the Medical Clinician/Principal Investigator [INVESTIGATOR_847809] . The Safety/Medical Monitor will prepare a UADE safety report summarizing the event and 
this will be distributed to all site Principal Investigators.   
Each of the sites has established practices for managing medical and psychiatric emergencies, 
and the research staff will continue to utilize these procedures. Treatment providers at each site 
will be responsible for monitoring participants for possible clinical deterioration or other problems, and for implementing appropriate courses of action. 
 Data and Safety Monitoring Board (DSMB)  
An independent CTN DSMB will examine accumulating data to assure protection of participants’ safety while the study’s scientific goals are being met. The CTN DSMB is responsible for 
conducting periodic reviews of accumulating safety and efficacy data. It will determine whether there is support for continuation of the trial, or evidence that study procedures should be changed, 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
74 or if the trial should be halted, for reasons relating to the safety of the study participants, the 
efficacy of the treatment under study, or inadequate trial performance (e.g., poor recruitment).  
 Safety Monitor/Medical Monitor  
The CCC Safety Monitor/Medical Monitor is responsible for reviewing all AEs , SAEs  and UADEs  
reported. All SAEs  and UADEs  will be reviewed with in one business day of being reported in the 
EDC. The Safety/Medical Monitor will also indicate concurrence or not with the details of the report 
provided by [CONTACT_779]. Where further information is needed the Safety Monitor/Medical Monitor will discuss the event with the site. Reviews of SAEs  and UADEs  will be conducted in the Advantage  
eClinical data system and will be a part of the safety database. All AEs are reviewed on a weekly 
basis to observe trends or unusual events.  
The CCC Safety Monitor/Medical Monitor will in turn summarize each SAE/UADE  and report the  
narrative to the sponsor  within pre -defined timelines, and if an event meets the criteria for 
expedited reporting, this will be provided to the site investigator to report to the IRB . Written SAE 
and UADE  reports will be presented at Data Safety Monitoring Board (DSMB) meetings  and to 
the DSMB at any time per request .  
 Adverse Events (AEs)  
Standard definitions for adverse events and serious adverse events, their identification, 
characterization regarding severity and relationship to therapy and processing are described in Appendix A.  
Events captured on study specific forms  are not recorded separately as an AE, unless they meet 
the SAE definition. Any of these events that meet the definition of an SAE are reported on the 
AE/SAE form set. Any spontaneous reporting of withdrawal symptoms by [CONTACT_9893]: withdrawal symptoms reported at visits without scheduled specific structured questionnaires; and withdrawal symptoms not listed in the specific 
structured questionnaires reported at any visit.  
 Serious Adverse Events (SAEs)  
All safety events will be evaluated to determine if they meet the criteria for an SAE/UADE.  For the 
purposes of this study, admission for labor and delivery will be reported on a study specific form 
and will not be reported as an SAE.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
75 17.0 DATA MANAGEMENT 
 Design and Development  
This protocol will utilize a centralized Data and Statistics Center (DSC). The DSC will be 
responsible for development of the electronic case report forms (eCRFs), development and validation of the clinical study database, ensuring data integrity, and training site and participating node staff on applicable data management procedures. Advantage eClinical, a web- based 
distributed data entry system, along with ePRO  for mobile surveys, will be implemented. Systems 
will be developed to ensure that guidelines and regulations surrounding the use of computerized systems used in clinical trials are upheld. The remainder of this section provides an overview of 
the data management plan associated with this protocol.  
 Site Responsibilities  
The data management responsibilities of each individual site will be specified by [CONTACT_847857]’s Guide.  
 Data Center Responsibilities  
The DSC will 1) develop a data management plan and will conduct data management activities 
in accordance with that plan, 2) provide final guided source documents and eCRFs for the collection of all data required by [CONTACT_1758], 3) develop data dictionaries f or each eCRF that will 
comprehensively define each data element, 4) conduct ongoing data monitoring activities on study data from all participating sites, 5) monitor any preliminary analysis data cleaning activities 
as needed, and 6) rigorously monitor final study data cleaning.  
 Data Collection  
Data will be collected at the study sites on source documents and entered by [CONTACT_847858]. In the event that 
Advantage eClinical is not available, the DSC will provide the sites with a final set of guided source 
documents and completion instructions.  Data entry into Advantage eClinical should be completed 
according to the instructions provided and project specific training. The investigator is responsible for maintaining accur ate, complete and up -to-date records, and for ensuring the  timely  completion 
of the eCRFs for each research participant. In some situations, data collected on source documents will not be entered into Advantage eClinical, but when it is entered, it will follow the guidelines stated above. Data from the actigraph devices will be uploaded from each device and sent to the DSC; information about CBT module usage will be sent directly from the vendor to the DSC. Finally , where applicable,  EEG data will be sent via secure file transfer from each site to 
University of [LOCATION_007] Southwest for analysis.  EEG data will be sent to the DSC via secure file 
transfer to be archived and preserved for Data Share. 
Mobile survey data will be completed by [CONTACT_847859]. 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
76 
 Data Acquisition and Entry  
Completed forms and electronic data will be entered into the Advantage eClinical system in 
accordance with the Advantage eClinical User’s Guide. Only authorized individuals shall have 
access to eCRFs.  
 Data Editing  
Completed data will be entered into Advantage eClinical. If incomplete or inaccurate data are 
found, a query will be generated to the sites for a response. Sites will resolve data inconsistencies 
and errors and enter all corrections and changes into Advantage  eClinical. Mobile survey data 
will be monitored for completeness and data quality to the extent possible as these self -reported 
assessments will be completed remotely by [CONTACT_4317]. As noted above, if participants complete more than one mobile survey within a [ADDRESS_1178746] entered for the day will be 
retained for analysis.  
 Data Transfer/Lock  
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted to and stored at the DSC. This will not include the participant’s 
contact [CONTACT_1290]. Rather, individual participants and their research data will be 
identified by a unique study identification number. The study data entry and study management 
systems used by [CONTACT_200888].  
Data will be transmitted by [CONTACT_268654]. 
The DSC will conduct final data quality assurance checks and “lock” the study database from further modification. The final analysis dataset will be returned to NIDA, as requested, for storage 
and archive.  
 Data Training  
The training plan for  research staff includes provisions for training on assessments, eCRF 
completion guidelines, data management procedures, and the use of Advantage eClinical. 
 Data Quality Assurance  
To address the issue of data entry quality, the DSC will follow a standard data monitoring plan. 
An acceptable quality level prior to study lock or closeout will be established as a part of the data management plan. Data quality summaries will be made available during the course of the 
protocol.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
77 18.0 DATA SHARING, PUBLIC ACCESS AND PUBLICATIONS  
This study will comply with the NIH Data Sharing Policy and Implementation Guidance 
(https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm ).  
Investigators will also register and report results of the trial in ClinicalTrials.gov, consistent with 
the requirements of the Policy on the Dissemination of NIH -Funded Clinical Trial Information and 
the Clinical Trials Registration ( https://grants.nih.gov/policy/clinical -
trials/reporting/understanding/nih- policy.htm ). 
Primary data for this study will be available to the public in the NIDA data repository, per NIDA 
CTN policy. For more details on data sharing please visit https://datashare.nida.nih.gov/ . 
The primary outcome(s) publication will be included along with study underlying primary data in 
the data share repository, and it will also be deposited in PubMed Central 
http://www.pubmedcentral.nih.gov/ per NIH Policy (http://publicaccess.nih.gov/) . 
The planning, preparation, and submission of publications will follow the policies of the 
Publications Committee of the CTN.  
NIDA CTN-0108   Version 7.0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
78 19.0 PROTOCOL SIGNATURE [CONTACT_362581]’S REPRESENTATIVE (CCTN SCIENTIFIC OFFICER OR  DESIGNEE)  
     
          
Printed Name   [CONTACT_360335] [CONTACT_9929]:  
• I am in receipt of version 6.[ADDRESS_1178747] this clinical study in 
accordance with the design and provisions specified therein.  
• I agree to follow the protocol as written except in cases where necessary to protect 
the safety, rights, or welfare of a participant, an alteration is required, and the sponsor 
and IRB have been notified prior to the action.  
• I will ensure that the requirements relating to obtaining informed consent and 
institutional review board (IRB) review and approval in 45 CFR 46 are met.  
• I agree to personally conduct or supervise this investigation at this site and to ensure 
that all site staff assisting in the conduct of this study are adequately and appropriately 
trained to implement this version of the protocol and that they are qualifi ed to meet the 
responsibilities to which they have been assigned.  
• I agree to comply with all the applicable federal, state, and local regulations regarding 
the obligations of clinical investigators as required by [CONTACT_9092] (HHS), the state, and the IRB.  
 
SITE’S PRINCIPAL INVESTIGATOR  
          
[INVESTIGATOR_847810]-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
79 20.0 REFERENCES 
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 
Arlington, VA: 2013.  
Atkinson A, Anderson Z, Hughes K, Bellis MA, Sumnall H, Syed Q. Interpersonal violence and 
illicit drugs. 2009. 
http://www.who.int/violenceprevention/interpersonal_violence_and_illicit_drug_use.pdf . 
Bjelland I, Dahl AA, Tangen Haug T, Neckelmann D. The validity of the Hospi[INVESTIGATOR_58900]: An updated literature review. J Psychosomatic Res 2002; 52(2):69- 77. 
Bolloni C, Panella R, Pedetti M, et al. Bilateral Transcranial Magnetic Stimulation of the 
Prefrontal Cortex Reduces Cocaine Intake: A Pi[INVESTIGATOR_16116]. Front Psychiatry 2016; 7: 133. 
Brown, Lawrence D., T. Tony Cai, and Anirban DasGupta. "Interval estimation for a binomial 
proportion." Statistical science (2001): 101 -117. 
Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ. The Pi[INVESTIGATOR_2272]: A new instrument for psychiatric practice and research. Psychiatry Research 1989; 
28:193- 213.  
Cadet JL, Bisagno V. Neuropsychological Consequences of Chronic Drug Use: Relevance to Treatment Approaches. Front Psychiatry 2015; 6: 189. 
Cohen, J. Statistical power analysis for the behavioral sciences. 2
nd ed. Hillsdale, NJ: Erlbaum; 
1988.  
Conde V, Tomasevic L, Akopi[CONTACT_1629] I, Stanek K, Saturnino GB, Thielscher A, et al. The non-
transcranial TMS -evoked potential is an inherent source of ambiguity in TMS -EEG studies. 
Neuroimage. 2019;185:300- 12. 
Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379(9810): 55- 70.  
Degenhardt L, Stockings E, Strang J, Marsden J, Hall WD. Illicit drug dependence. In: Patel V, Chisholm D, Dua T, Laxminarayan R, Medina- Mora ME, eds. Mental, Neurological, and 
Substance Use Disorders: Disease Control Priorities. 3rd ed. Washington D.C.: The International Bank for Reconstruction and Development / The World Bank; 2016.  
Duecker F, Sack AT. Rethinking the role of sham TMS. Front Psychol. 2015;6:210.  
Ekhtiari H, Tavakoli H, Addolorato G, et al. Transcranial Electrical and Magnetic Stimulation (tES and TMS) for Addiction Medicine: A consensus paper on the present state of the science 
and the road ahead. Neurosci Biobehav Rev  2019 Sep;104:118- 140. doi:  
10.1016/j.neubiorev.2019.06.007. Epub 2019 Jul 2.  
Enokibara M, Trevizol A, Shiozawa P, Cordeiro Q. Establishing an effective TMS protocol for craving in substance addiction: Is it possible? Am J Addict 2016; 25(1): 28- 30. 
NIDA CTN-0108   Version 7.0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
80 Eryilmaz G, Sayar GH, Ozten E, Gul IG, Yorbik O, Isiten N, et al. Follow -up study of children 
whose mothers were treated with transcranial magnetic stimulation during pregnancy: 
preliminary results. Neuromodulation. 2015;18(4):255- 60. 
Frazer KM, Richards Q, Keith DR. The long- term effects of cocaine use on cognitive functioning: 
A systematic critical review. Behav Brain Res 2018; 348: [ADDRESS_1178748]. 2016;32(3):169 -73. 
Goldstein, Harvey, William Browne, and Jon Rasbash. "Partitioning variation in multilevel 
models." Understanding statistics: statistical issues in psychology, education, and the social 
sciences 1.4 (2002): 223 -231. 
Grall- Bronnec M, Sauvaget A. The use of repetitive transcranial magnetic stimulation for 
modulating craving and addictive behaviours: a critical literature review of efficacy, technical and methodological considerations. Neurosci Biobehav Rev 2014; 47: 592 -613.  
Hanlon CA, Dowdle LT, Henderson JS. Modulating Neural Circuits with Transcranial Magnetic 
Stimulation: Implications for Addiction Treatment Development. Pharmacol Rev 2018; 70(3): 
661-83. 
Hanlon CA et al. Left frontal pole theta burst stimulation decreases orbitofrontal and insula 
activity in cocaine users and alcohol users.  Drug Alcohol Depend, 2017;178:310- 317. 
Harper, Alison. World Health Organization. WHOQOL -BREF: Introduction, Administration, 
Scoring, and Generic Version of the Assessment. Field Trial Version. 1996; 1 -18. Programme 
on Mental Health: Geneva.  
Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 
86(9):1119- 27. 
Hizli Sayar G, Ozten E, Tufan E, Cerit C, Kagan G, Dilbaz N, et al. Transcranial magnetic stimulation during pregnancy. Arch Womens Ment Health. 2014;17(4):311- 5. 
Krebs EE, Lorenz KA, Bair MJ, Damush TM, Wu J, Sutherland JM, Asch SM, Kroenke 
K.Development and initial validation of the PEG, a three- item scale assessing pain intensity and  
interference. Journal of general internal medicine. 2009 Jun 1;24(6):733- 8. 
Lerner I, Ketz NA, Jones AP, Bryant NB, Robert B, Skorheim SW, et al. Transcranial Current Stimulation During Sleep Facilitates Insight into Temporal Rules, but does not Consolidate Memories of Individual Sequential Experiences. Sci Rep. 2019;9(1):1516.  
Levkovitz Y, Isserles M, Padberg F, Lisanby [INVESTIGATOR_68991], By[CONTACT_67002] A, Xia G, et al. Efficacy and safety of 
deep transcranial magnetic stimulation for major depression: a prospective multicenter 
randomized controlled trial. World Psychiatry. 2015;14(1):64 -73. 
Liang Y, Wang L, Yuan TF. Targeting Withdrawal Symptoms in Men Addicted to Methamphetamine With Transcranial Magnetic Stimulation: A Randomized Clinical Trial. JAMA Psychiatry 2018; 75(11): 1199- 201. 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178749] KP, Gonzalez R, Feldstein Ewing SW, Nixon SJ, Tapert S, 
Bartsch H, Goldstein RZ, Heitzeg M. Adolescent brain cognitive development (ABCD) study: 
Overview of substance use assessment methods. Dev Cogn Neurosci. 2018 Aug;32:80- 96. doi: 
10.1016/j.dcn.2018.02.007. Epub 2018 Feb 21. PMID: 29559216; PMCID: PMC6375310.  
Liu T, Li Y, Shen Y, Liu X, Yuan TF. Gender does not matter: Add- on repetitive transcranial 
magnetic stimulation treatment for female methamphetamine dependents. Prog 
Neuropsychopharmacol Biol Psychiatry 2019; 92: 70- 5.  
Loo CK, McFarquhar TF, Mitchell PB. A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression. Int J Neuropsychopharmacol. 2008;11(1):131 -
47. 
McClintock SM, Reti IM, Carpenter LL, McDonald WM, Dubin M, Taylor SF, et al. Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation 
(rTMS) in the Treatment of Depression. J Clin Psychiatry. 2018;79(1).  
Mennemeier M, Triggs W, Chelette K, Woods A, Kimbrell T, Dornhoffer J. Sham Transcranial 
Magnetic Stimulation Using Electrical Stimulation of the Scalp. Brain Stimul. 2009;2(3):168- 73. 
Morley KC, Cornish JL, Faingold A, Wood K, Haber PS. Pharmacotherapeutic agents in the 
treatment of methamphetamine dependence. Expert Opin Investig Drugs 2017; 26(5): 563 -78. 
Mudoni A, Caccetta F, Caroppo M, et al. [Acute kidney injury and rhabdomyolysis after cocaine 
overdose: case report and literature review]. G Ital Nefrol 2018; 35(2).  
O'Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic 
stimulation in the acute treatment of major depression: a multisite randomized controlled 
trial. Biol Psychiatry . 2007;62(11):1208 -1216. doi:10.1016/j.biopsych.2007.01.018  
Palamar JJ, Han BH, Keyes KM. Trends in characteristics of individuals who use methamphetamine in the [LOCATION_002], 2015 -2018. Drug Alcohol Depend. 2020;213:108089.  
Parvaz MA, Moeller SJ, Goldstein RZ. Incubation of Cue- Induced Craving in Adults Addicted to 
Cocaine Measured by [CONTACT_847860]. JAMA Psychiatry. 2016;73(11):1127- 34. 
Paulus M, Saxon AJ, Hermann R. Methamphetamine use disorder: Epi[INVESTIGATOR_623], clinical manifestations, course, assessment, and diagnosis. UpToDate 2018; August.  
Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C -CASA): Classification of suicidal events in the FDA’s pediatric suicidal risk 
analysis of antidepressants. Am J Psychiatry 2007; 164(7): 1035 -1043.  
Rachid F. Repetitive Transcranial Magnetic Stimulation and Treatment- emergent Mania and 
Hypomania: A Review of the Literature. J Psychiatr Pract. 2017;23(2):150- 9. 
Rao M, Nomura S. TMS in treatment of cocaine use disorder. Brain Stimulation: Basic, 
Translational, and Clinical Research in Neuromodulation 2019; 12(2): 540.  
Rapi[INVESTIGATOR_156454] C, Del Casale A, Di Pi[INVESTIGATOR_52468] S, et al. Add -on high frequency deep transcranial magnetic 
stimulation (dTMS) to bilateral prefrontal cortex reduces cocaine craving in patients with cocaine 
use disorder. Neurosci Lett 2016; 629: 43- 7.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
82 Roenneberg, T., Wirz -Justice, A., & Merrow, M. (2003). Life between clocks: daily temporal 
patterns of human chronotypes. J Biol Rhythms, 18(1), 80 -90. 
Rossi S, Ferro M, Cincotta M, Ulivelli M, Bartalini S, Miniussi C, et al. A real electro -magnetic 
placebo (REMP) device for sham transcranial magnetic stimulation (TMS). Clin Neurophysiol. 
2007;118(3):709 -16. 
Rossi S, Hallett M, Rossini PM, Pascual- Leone A.  Safety, ethical considerations, and 
application guidelines for the use of transcranial magnetic stimulation in clinical practice and 
research.  Clin Neurophysiol, 2009; 120:2008 -2039.  
Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini -International Neuropsychiatric Interview 
(M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for 
DSM -IV and ICD -10. J Clin Psychiatry 1998; [ADDRESS_1178750] 20:22- 33.  
Sheffer CE, Mennemeier MS, Landes RD, Dornhoffer J, Kimbrell T, Bickel WK, et al. Focal 
electrical stimulation as an effective sham control for active rTMS and biofeedback treatments. 
Appl Psychophysiol Biofeedback. 2013;38(3):171 -6. 
Sobel L, Sobel M. Timeline follow -back: a technique for assessing self -reported alcohol  
consumption. In: Litten R, Allen J, eds. Measuring Alcohol Consumption: Psychosocial and 
Biological Methods. Totowa, NJ: Humana Press; 1992:41- 72. 
Steele VR et al.  Report of transient events in a cocaine- dependent volunteer who received 
iTBS.  Brain Stimulat., 2018;11:[ADDRESS_1178751] 
stimulation as a treatment for cocaine use disorder: A proof of concept study.  Front. Neurosci, 
2019; 13.  
Steele V, Maxwell A, Ross T, Salmeron B, Stein E. Preliminary evidence for accelerated 
intermittant theta -burst stimulation as a treatment for cocaine use disorder. Brain Stimulation: 
Basic, Translational, and Clinical Research in Neuromodulation 2019; 12(2): 574.  
Stewart JL, May AC. Electrophysiology for addiction medicine: From methodology to conceptualization of reward deficits. Prog Brain Res. 2016;224:67 -84. 
Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci 2001; 21(15): RC157.  
Substance Abuse and Mental Health Services Administration.  The National Survey on Drug Use 
and Health:2018. 
https://www.samhsa.gov/data/sites/default/files/cbhsq -reports/Assistant -
Secretary -nsduh2018 . 
Terraneo, Alberto, et al. "Transcranial magnetic stimulation of dorsolateral prefrontal cortex 
reduces cocaine use: A pi[INVESTIGATOR_799] ." European neuropsychopharmacology: the journal of the 
European College of Neuropsychopharmacology vol. 26,1 (2016): 37- 44. 
Toll RT, Wu W, Naparstek S, Zhang Y, Narayan M, Patenaude B, et al. An Electroencephalography Connectomic Profile of Posttraumatic Stress Disorder. Am J Psychiatry. 2020;177(3):233- 43. 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
83 Trivedi MH, Wisniewski SR, Morris DW et al. Concise Health Risk Tracking scale: a brief self -
report and clinician rating of suicidal risk. J Clin Psychiatry 2011; 72(6):757- 64.  
Wittman M, Paulus M, Roenneberg T. Decreased psychological well -being in late ‘chronotypes’ 
is mediated by [CONTACT_847861]. Substance Use & Misuse 2010; 45:15 -30.  
Zangen, Abraham, and Mark George. "3- Weeks of Prefrontal and Insular Deep TMS Combined 
With Cue -Induced Craving Significantly Increases Smoking Abstinence: Results From an 
International, Multi -Site, Randomized, Sham Controlled Trial."  Biological Psychiatry  87.9 (2020): 
S129.  
Zigmond AS, Snaith RP. The hospi[INVESTIGATOR_56105]. Acta Psychiatr Scand1983; 
67(6):361- 70. 
NIDA CTN-0108   Version 7.0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
84 21.0 APPENDIX A: ADVERSE EVENT REPORTING AND 
PROCEDURES  
Each participating site’s Principal Investigator [INVESTIGATOR_9835], including 
ensuring human research subject protection by [CONTACT_556206], report, and monitor adverse events.  
Definition of Adverse Events, Serious Adverse Events and Unanticipated Adverse Device 
Effects  
An adverse event  (AE) is any untoward medical occurrence in humans, whether or not 
considered study device  related which occurs during the conduct of a clinical trial. Any change 
from baseline in clinical status, ECGs, lab results, x -rays, physical examinations, etc., that is 
considered clinically significant by [CONTACT_941] s ite Medical Clinician are considered AEs . 
Suspected adverse reaction  is any adverse event for which there is a reasonable possibility that 
the study device  caused the adverse event. A reasonable possibility implies that there is evidence 
that the study device  caused the event.  
Adverse reaction  is any adverse event caused by [CONTACT_19911] . 
Unanticipated adverse device effect  (UADE) is any serious adverse effect on health or safety 
or any life- threatening problem or death caused by, or associated with, a device, if that effect, 
problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other 
unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects (21 CFR 81 2.3(s)).  
An adverse event, suspected adverse reaction, or  adverse reaction  is considered “ serious” 
(i.e., a serious adverse event, serious suspected adverse reaction or serious adverse reaction) if, 
in the view of either the s ite Medical Clinician or sponsor, it:  
1) Results in death: A death occurring during the study or which comes to the attention of 
the research staff during the protocol -defined follow -up period, whether or not 
considered caused by [CONTACT_19911], must be reported.  
2) Is life -threatening: Life -threatening means that the study participant was, in the opi[INVESTIGATOR_41657] M edical Clinician or sponsor, at immediate risk of death from the reaction as it 
occurred and required immediate intervention.  
3) Requires inpatient hospi[INVESTIGATOR_1081].  
4) Results in persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions.  
5) Is a congenital abnormality or birth defect.  
NIDA CTN-0108   Version 7.0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
85 6) Important medical event that may not result in one of the above outcomes  but may 
jeopardize the health of the study participant or require medical or surgical intervention 
to prevent one of the outcomes listed in the above definition of serious event.   
Definition of Expectedness 
Any adverse event is considered “unexpected” if it is not listed in the investigator brochure,  
package insert or product safety summary or is not listed at the specificity or severity that has 
been observed. If neither is available,  then the protocol and consent are used to determine an 
unexpected adverse event.  
Pregnancy 
Any pregnancies that occur while a participant is enrolled in the study will be captured on a 
pregnancy CRF and not separately reported as an AE or SAE. Women who become pregnant 
during the active treatment period will be discontinued from further rTMS procedures , referred for 
medical care, and the pregnancy followed until an outcome is known.  
Medical and Psychiatric History  
A thorough medical and psychiatric history during the screening phase should record any chronic, 
acute, or intermittent preexisting or current illnesses, diseases, symptoms, or laboratory signs of 
the participant, to avoid reporting pre- existing conditions as new AEs and to assist in the 
assessment of worsening in int ensity or severity of these conditions that would indicate an AE. 
Stable chronic conditions, such as arthritis, which are present prior to clinical trial entry and do 
not worsen are not considered AEs.  
Site’s Role in Eliciting and Reporting Adverse Events  
Appropriately qualified and trained personnel will elicit participant reporting of AEs , SAEs  and 
UADEs  at each study visit designated to collect AEs . Participants will be asked specifically about 
common adverse events associated with device use including headaches, device application site 
pain and hearing changes. Adverse event (medical and/or psychiatric) assessment will initiate 
with participant consent and follow -up of ongoing adverse events will continue through resolution 
or [ADDRESS_1178752] study vis it. Study personnel will obtain as much information as possible about 
the reported AE/SAE to complete the AE/SAE forms and will consult  with the Safety 
Monitor/Medical Monitor  as warranted.  
Standard reporting, within 7 days of the site becoming aware of the event, is required for 
reportable AEs. Expedited reporting (within 24 hours of their occurrence and/or site's knowledge 
of the event) is required for reportable SAEs (including death and l ife-threatening events). S ites 
are responsible for reporting SAEs to the IRB  of record , per the IRB  of record’s  guidelines.  For 
device studies , the Site Principal Investigators are required to submit a safety  report of a UADE 
to the IRB of record as soon as possible, but in no event later than [ADDRESS_1178753] learns of the event (§ 812.150(a)(1)).  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
86 Sites are required to enter reportable AEs and all SAE/UADE s in the Advantage eClinicalSM 
system. The AE form is used to capture reportable AEs (as defined in the protocol). Additional 
information may need to be gathered to evaluate SAEs and to complete the appropriate CRFs 
and the summary. This process may include obtaining hospi[INVESTIGATOR_9837], medical 
records, autopsy records or any other type records or information necessary to provide a complete and clear pi[INVESTIGATOR_9838]. If the SAE is not resolved or stable at the time of the initial report or if new information becomes available after 
the initial report, follow -up information must be submitted as soon as possible.  
Reportable adverse events will be followed until resolution, stabilization or study end. Sites should 
make every effort to follow each SAE /UADE  until a known outcome is determined, even beyond 
the end of the study as necessary. An unknown outcome of an SAE is strongly discouraged. 
Site’s Role in Assessing Severity and Causality of Adverse Events  
Appropriately qualified and trained study personnel will conduct an initial assessment of 
seriousness, severity, and causality when eliciting participant reporting of adverse events. A study Medical Clinician will review reportable AEs for seriousness, severity, and causality on at least a 
weekly basis.  
Guidelines for Assessing Severity  
The severity of an adverse event refer s to the intensity of the event:  
Grade 1  Mild Transient or mild discomfort (typi[INVESTIGATOR_897] < 48 hours), no or minimal 
medical intervention/therapy required, hospi[INVESTIGATOR_266772] 
(non- prescription or single- use prescription therapy may be 
employed to relieve symptoms, e.g., aspi[INVESTIGATOR_266773], acetaminophen for post -surgical pain)  
Grade 2  Moderate  Mild to moderate limitation in activity some assistance may be 
needed; no or minimal intervention/therapy required, hospi[INVESTIGATOR_7975], but unlikely  
Grade 3  Severe  Marked limitation in activity, some assistance usually required; 
medical intervention/ therapy required hospi[INVESTIGATOR_847811] s ite Medical Clinician  will use the following question when assessing causality of an adverse 
event to study device where an affirmative answer designates the event as a suspected adverse 
reaction:  
Is there a reasonable possibility that the study device caused the event?  
NIDA CTN-0108   Version 7.0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
87 Site’s Role in Monitoring Adverse Events  
Local quality assurance monitors will review study sites and respective study data on a regular 
basis and will promptly advi se sites to report any previously unreported safety issues and ensure 
that the reportable safety -related events are being followed to resolution and reported 
appropriately. Staff education, re -training or appropriate corrective action plan will be 
implement ed at the participating site when unreported or unidentified reportable AEs or serious 
events are discovered, to ensure future identification and timely reporting by [CONTACT_779].  
Sponsor’s Role in Safety Management Procedures of AEs/SAEs/UADEs  
A NIDA -assigned Safety Monitor/ Medical Monitor is responsible for reviewing all serious adverse 
event reports. All reported SAEs will generate an e- mail notification to the Medical Monitor, Lead 
Investigator, and designees. All SAEs will be reviewed by [CONTACT_34346]/ Medical Monitor in 
Advantage eClinicalSM and, if needed, additional information will be requested. The Safety 
Monitor/ Medical Monitor will also report events to the sponsor and the DSMB. The DSMB will 
receive summary reports of all adverse events annually, at a minimum. The DSMB or the CCC 
Safety Monitor/ Medical Monitor may also request additional and updated information. Details 
regarding specific adverse events, their treatment and resolution, will be summarized by [CONTACT_34346]/ Medical Monitor in writing for review by [CONTACT_565130]. Subsequent 
review by [CONTACT_34346]/ Medical Monitor DSMB and ethics review committee or IRB, the 
sponsor, or relevant local regulatory authorities may also suspend further trial treatment at a s ite. 
The study sponsor  and DSMB retain the authority to suspend additional enrollment and 
treatments for the entire study as applicable.  The device or study spons or will be responsible for 
providing initial device safety information and updated safet y information during the study for site 
investigators and all reviewing IRBs.  
Regulatory Reporting for an abbreviated IDE  study 
It is anticipated that this study will fall under an abbreviated IDE in which the IRB of record (MUSC 
as the sIRB) will assume responsibility for oversight. If an SAE meets the expedited reporting 
criteria (serious , unexpected and possibly related to the intervention, e.g., UADE ), the Safety 
Monitor/ Medical Monitor on behalf of the sponsor will prepare an expedited report (MedWatch 
Form 3500 or similar) for the IRB as soon as possible and no later than [ADDRESS_1178754] apply his/her clinical judgment to determine whether or not an 
adverse event is of sufficient severity to require that the participant be withdrawn from further 
study intervention. The s ite Medical Clinician  should consult with the site Principal Investigator, 
the Lead Investigator and/or Safety Monitor/ Medical Monitor as needed. If necessary, a s ite 
Medical Clinician  may suspend any trial treatments and institute the necessary medical therapy 
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178755] a participant from any immediate danger. A participant may also voluntarily withdraw 
from treatment due to what he/she perceives as an intolerable adverse event or for any other 
reason. If voluntary withdrawal is requested, the participant will be asked to complete an end of 
rTMS/sham  visit to assure safety and to document outcomes and will be given recommendations 
for medical care and/or referrals to treatment, as necessary.  
 Adverse Event Reporting (Chart)  
 
  
NIDA CTN-0108   Version 7.0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ 2023 
 
CONFIDENTIAL  
89 22.0 APPENDIX B: DATA AND SAFETY MONITORING PLAN  (DSMP)  
1.0 Brief Study Overview  
Approximately 160 adults will be enrolled in this 8-week, double -blind, sham -controlled trial of 
rTMS in the treatment of adults with moderate to severe CUD or MUD.  Participants will receive 
up to 30 rTMS/sham sessions over the [ADDRESS_1178756] randomization.  The 
objectives of this study are to determine the feasibility and gather preliminary data on the efficacy 
of rTMS for individuals with CUD or MUD.  
2.0 Oversight of Clinical Responsibilities  
A. Site Principal Investigator  
[INVESTIGATOR_9842]’s Principal Investigator (PI) is responsible for study oversight, including 
ensuring human research subject protection by [CONTACT_9939], trained 
research staff and Medical Clinician s to assess, report, and monitor adverse events.  
All adverse events (AEs) occurring during the course of the clinical trial will be collected, 
documented, and reported by [CONTACT_9940]- investigators according to the Protocol.  
The occurrence of AEs , serious adverse events (SAEs) and UADEs will be assessed at each 
clinic visit during the study. SAEs  will be followed until considered resolved or stable.  
Reportable AEs are required to be entered into the data system within 7 days of the research staff 
becoming aware of the event. Reportable SAEs /UADEs  (including death and life- threatening 
events) are required to be entered into the data system within 24 hours of site's knowledge of the 
event).  
B. CCC Safety Monitor/ Medical Monitor  
The NIDA CTN Clinical Coordinating Center’s (CCC) Safety Monitor/ Medical Monitor or designee 
is responsible for reviewing all AEs, SAEs and UADEs  reported. The CCC Safety Monitor/ Medical 
Monitor is alerted via email each time an SAE /UADE  is reported in the EDC. All SAEs will be 
reviewed at the time they are reported in the EDC. The Safety Monitor/ Medical Monitor or 
designee will also indicate concurrence or not with the details of the report provided by [CONTACT_47808]. Where further information is needed the Safety Monitor/ Medical Monitor or designee will 
discuss the event with the research staff. Reviews of SAEs by [CONTACT_200893]/ Medical 
Monitor or designee will be documented in the Advantage eClinicalSM  data system and will be a 
part of the safety database. All AEs are reviewed on a weekly basis to observe trends or unusual 
events.  
NIDA CTN-0108   Version 7.0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178757] (MUSC 
as the sIRB) will assume responsibility for oversight. If an SAE meets the expedited reporting 
criteria (serious, unexpected and possibly related to the i ntervention, e.g. , UADE ), the Safety 
Monitor/Medical Monitor on behalf of the sponsor will prepare an expedited report (MedWatch 
Form 3500 or similar) for the IRB as soon as possible and no later than [ADDRESS_1178758] (DSMB)  
The NIDA CTN DSMB affiliated with this trial will be responsible for conducting periodic reviews 
of accumulating safety, trial performance, and outcome data. Reports will be generated and presented for Data and Safety Monitoring Board (DSMB) meetings. The DSMB will receive listings 
of AEs and narratives  of all SAEs at a frequency requested by [CONTACT_4318], but at least annually.  
Furthermore, the DSMB will be informed of expedited reports of SAEs. The DSMB will make 
recommendations to NIDA CCTN as to whether there is sufficient support for continuation of the 
trial, evidence that study procedures should be changed, or evidence that the trial (or a specific 
site) should be halted for reasons relating to safety of the study participants or inadequate trial 
performa nce (e.g., poor recruitment).  
Following each DSMB meeting, the NIDA CCTN will communicate the outcomes of the meeting, 
based on DSMB recommendations, in writing to the study Lead Investigator. This communication 
summarizing study safety information will be submitted to the sIRB and disseminated to 
participating sites . 
D. Quality Assurance (QA) Monitoring  
The monitoring of the study site(s) will be conducted on a regular basis using a combination of 
NIDA CCTN CCC monitors  and local Node  QA monitors . Investigators will host periodic visits for 
the monitors and local Node QA monitors . The purpose of these visits is to assess compliance 
with GCP requirements and to document the integrity of the trial progress. The investigative site 
will provide direct access to all trial related sites (e.g., pharmacy, research office), source data/documentation, and reports for the purpose of monitoring and auditing by [CONTACT_85231], as well as for inspection by [CONTACT_3482]. Areas of particular conc ern will be the 
review of inclusion/exclusion criteria, participant Informed Consent Forms, protocol adherence, 
safety monitoring, IRB reviews and approvals, regulatory documents, participant records, and site 
Principal Investigator [INVESTIGATOR_9815]. The monitors will interact with the research staff to identify issues and re -train the site as needed to enhance research quality.  
QA Site Visit Reports will be prepared by [CONTACT_200894]. These 
reports will be sent to the site Principal Investigator, the study Lead Investigator and NIDA CCTN.  
Local Node site visit reports are sent to those entities required of them by [CONTACT_847862], generally including the Lead Investigator, site Principal Investigator, Node PI [INVESTIGATOR_1238] a CCC 
representative, usually the Clinical Study Manager  for the study.  
NIDA CTN-0108   Version 7.0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178759] participant identifiers on 
site, as well as secure computing procedures for entering and tr ansferring electronic data. The 
documents or logs linking the study codes with the study participant on site will be kept locked 
separately from the study files and the medical records. No identifying information will be 
disclosed in reports, publications or presentations.  
Information Meeting Reporting Requirements  
The consent form will specifically state the types of information that are required for reporting and 
that the information will be reported as required. These include suspected or known sexual or 
physical abuse of a child or elders, or threatened violence to self and/or others.  
Participant Protection  
The site’s study clinician will evaluate all pertinent screening and randomization assessments 
prior to participant randomization to ensure that the participant is eligible and safe to enter the 
study. AEs and concomitant medications will be assessed and documented at each study  visit. 
Individuals who experience an AE that compromises safe participation in a study will be discontinued from further  rTMS intervention and provided referrals for other treatment or to 
specialized care. Study personnel will request that the participant complete an end- of- interve ntion 
visit to assure safety and to document end- of-intervention outcomes.  
Pregnancy  
A positive pregnancy test post -randomization will result in the cessation of rTMS /sham  treatment . 
The research staff will follow the participant until an outcome of the pregnancy is known and 
reported.  
Study Specific Risks  
rTMS is a well- tolerated, non- invasive intervention. Although there is a theoretical risk of seizure, 
seizures have not been reported using current rTMS safety procedures. The most common side 
effects are headache and mild scalp discomfort where the magne tism is applied. O ther possible 
side effects include temporary hearing loss (which will be mitigated by [CONTACT_809960]), and 
changes in mood.  Participants will be asked not to participate in any other formal treatment for 
CUD or MUD, besides self -help gr oups, while they are in this study. As such, there may be some 
risk of drug use that might have been avoided if the individual were engaged in a formal SUD treatment program.  However, all participants will receive access to and are encouraged to 
participate in a CBT for SUDs which will be provided to all study participants.  
3.0 Data Management Procedures  
This protocol will utilize a centralized Data and Statistics Center (DSC). A web- based distributed 
data entry model will be implemented. Advantage eClinical
SM will be utilized as the electronic data 
NIDA CTN-0108   Version 7.0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178760] of the data. It will be developed to ensure that guidelines 
and regulations surrounding the use of computerized systems in clinical trials are upheld.  Data 
collection for mobile surveys may use a separate system and/or may not maintain 21CFR11 
compliance due to the lack of an audit trail; while not ideal, data is unlikely to be collected in its 
entirety, if at all, without relaxing this restriction.  
4.0 Data And Statistics Center Responsibilities  
The DSC will: 1) develop and apply data management procedures to ensure the collection of 
accurate and good- quality data, 2) provide source documents and electronic Case Report Forms 
(eCRFs) for the collection of all data collected in Advantage eClinical and mobile survey system 
(developed in ePRO) required by [CONTACT_1758], 3) develop data dictionaries for each eCRF that will 
comprehensively define each data element, 4) prepare instructions for the use of Advantage  
eClinicalSM and for the completion of eCRFs, 5) conduct ongoing monitoring activities on study 
data collected from all participating sites, and 6) perform data cleaning activities prior to the final 
study database lock.  
5.[ADDRESS_1178761] entry into the eCRF. If Advantage 
eClinicalSM is not available, the DSC will provide the sites with a final set of guided  source 
documents and completion instructions. Data will be entered into Advantage eClinicalSM in 
accordance with the instructions provided during protocol -specific training and guidelines 
established by [CONTACT_9928]. Data entry into the eCRFs is performed by [CONTACT_4539].  
Selected eCRFs may also require the Investigator’s signature (wet or electronic) . In some 
situations , data collected on source documents will not be entered into Advantage eClinicalSM, but 
when it is entered, it will follow the guidelines stated above. Data collected in the mobile survey 
system will be monitored for data quality to the extent possible as this data will be directly entered by [CONTACT_847863]- based survey system remotely.  
The Principal Investigator [INVESTIGATOR_200785], complete and up -to-
date research records.  In addition, the Principal Investigator [INVESTIGATOR_200786].  
6.[ADDRESS_1178762] as is.  
NIDA CTN-0108   Version 7 .0 
rTMS for Stimulant Use Disorders (STIMULUS )  11/10/ [ADDRESS_1178763] regular monitoring visits, during which,  audits 
comparing source documents to the data entered on the eCRF will be performed. Any 
discrepancies identified between the source document and the eCRF will be corrected by [CONTACT_779].  
Trial progress and data status reports, which provide information  items such as  on recruitment, 
availability of primary outcome, treatment exposure, attendance at long term follow -up visits, 
regulatory status, and data quality, will be generated daily and posted to a secure website. These 
reports are available to the site  staff, the l ocal node QA staff, the Lead Investigator, the 
coordinating centers, and NIDA CCTN, to monitor each sites’ progress on the study.  
7.0 Data Lock And Transfer  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the DSC. Individual participants and their research data will be identified by a unique study identification number; further, some identifiable data may 
be collected in eClinical. The study data entry and study management systems used by [CONTACT_200888].  
At the conclusion of data collection for the study, the DSC will perform final data cleaning activities and will “lock” the study database from further modification. The final raw dataset s will be 
transferred to the Lead Investigator or designee. De- identified versions of these datasets also will 
be provided to the NIDA CCTN -designated part y for storage and archiving. These datasets will 
also be posted on the NIDA Data Share website.  
Reference:  http://grants.nih.gov/grants/guide/notice- files/not98- 084.html
  